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1 Introduction 
1.1 The immune System 
The immune system is a system, which is composed of special cells, proteins, tissues, 
and organs that distinguishes host cells and tissues from foreign substances and 
provides protection against them.  
Pathogens can rapidly change and acclimatize to escape detection and destruction by 
the immune system. Therefore, the immune system has to continuously evolve, develop 
and optimize multiple defense mechanisms to identify and neutralize pathogens. One of 
the systems that evolve is the innate immune system [1]. 
 
1.1.1 Innate Immune System 
The innate immune system is the first line of defense, which contains many different 
types of cells, molecules and utilizes various mechanisms to protect host from 
pathogens and their toxins in a non-specific way [2]. The innate immunity is an 
evolutionarily ancient system of the host defense mechanisms. The same molecular 
modules were found in both plants and animals, indicating that it arose before the split of 
these two kingdoms [3]. 
Skin and the epithelia that line our internal organs are performing the first line of innate 
immune defense against attacking organisms (pathogens and commensal). The second 
line of defense is the innate immune cells, namely natural killer cells (NK cells); 
macrophages; dendritic cells (DCs); mast cells; neutrophils and eosinophils. These cells 
are able to recognize pathogens by their innate immune receptors and become active 
[2]. The adaptive immunity adds to the innate immune system a specific recognition of 
proteins, carbohydrates, lipids, nucleic acids, and pathogens [2]. 
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1.1.2 Pattern-Recognition Receptors 
The protection from infections needs complex immune responses involving the innate 
and the adaptive immune systems. The innate immune system has the key role in 
starting and arranging of host defenses by regulating the production of interferons, 
proinflammatory cytokines and antimicrobial effector molecules from the innate immune 
cells, which detect the pathogens by their innate immune receptors (pattern-recognition 
receptors (PRRs)).  
Many different types of PRRs have been discovered and their functions in the sensing of 
pathogens and pathogen molecules have been exposed. These include the Toll-like 
receptors (TLRs), the C-type lectin receptors, the RIG-like helicases, the NOD-like 
receptors (NLRs), the cytosolic DNA sensors DAI6, RNA polymerase III and AIM2.  
PRRs are expressed as transmembrane proteins or soluble in the cytosol. These 
receptors sense microbial pattern from bacteria, fungi, viruses and parasites. Activation 
of these receptors leads to trigger signaling pathways that regulate transcription of 
genes involved in the immune response, including nuclear factor (NF)-kappa B; mitogen-
activated protein kinases (MAPKs); and the type I interferon (IFN) response [4], [5], .[6], 
[7], [8], [9], [10], [11], [12]; [13].  
Understanding of the innate immune response has been significantly improved after 
identification of many families of PRRs. The Toll receptors are the first identified family 
of PRRs. Toll receptors were discovered in the fruit fly and are located either at the cell 
surface or within endosomes [5], [14]. The human homologs are the Toll like receptors 
(TLRs). These innate immune proteins establish a family of transmembrane receptors, 
which detect microbial associated molecular patterns (MAMPs) and danger associated 
molecular patterns (DAMPs), like lipopolysaccharides (LPS), DNA, RNA, ATP and uric 
acid [15].  
 
1.1.3 Nucleotide-Binding Oligomerization Domain Like Receptors (NLRs) 
The NLRs are a cytosolic family of MAMP and DAMP sensors. NLRs composed of a 
leucine rich repeat domain (LRR) for MAMPs and DAMPs detecting, a central nucleotide 
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binding and oligomerization domain (NOD=NACHT) for nucleotide triphosphate (NTP) 
binding and oligomerization, and an N-terminal domain for signal induction; like caspase 
recruitment domain (CARD) or a Pyrin domain (PYD) [16], [15].  
The human genome contains twenty-two NLRs genes. The NOD domain is the only 
common domain to all NLR family members [17]. The NLR family comprises three 
different subfamilies; the CARD-containing subfamily (NLRCs); like (NOD1-2), the Pyrin 
containing (NLRPs); such as (NLRP1-2) and the IPAF; like (NAIP), (figure 1.1) [17]. 
  
Figure 1.1: Domains arrangement of the NLR family. In human there are 22 members of NLR. The 
members have been categorized into different subfamilies NLRC, NLRP and IPAF. The NLR member 
consists of a variable N-terminal effector domain, a central domain NOD=NACHT, and an C-terminal LRR. 
NAD: NACHT=NOD-associated domain; X: Undefined domain; FIIND: Function-to-find domain; CIITA: MHC 
class II transactivator; AD: Acid transactivation domain; NAIP: Neuronal apoptosis inhibitor protein and BIR: 
Baculoviral inhibitory repeat [15]. 
 
1.1.4 Nucleotide-Binding Oligomerization Domain-Containing Protein 2 
Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is a member of 
NLRs family and belongs to NLRC superfamily. It functions as an intracellular receptor 
for the bacterial cell wall component muramyl dipeptide (MDP). NOD2 is also known as 
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caspase recruitment domain-containing protein 15 (CARD15) and inflammatory bowel 
disease protein 1 (IBD1). NOD2 was discovered twelve years ago [18] and is one of the 
most well studied members of the NLR family.  
Of interest, polymorphisms of the CARD15 gene, which encodes NOD2, are associated, 
among other diseases, with Crohn's disease [19]. NOD2 is expressed mainly in immune 
cells and in endothelial [20], [21]. 
Biochemical characterization of NOD2 indicates that it induces activation of NF-kappa B 
after stimulation in a TLR-independent manner [22], [23]. Further investigations revealed 
that NOD2 is the receptor for MDP. It is a molecule that originates from bacterial cell wall 
during synthesis and/or degradation of bacterial peptidoglycan (PGN) of the bacterial 
cell wall. MDP molecules are present in all Gram-positive and Gram-negative bacteria 
[24] [25].  
According to the studies on other NLRs, it is widely believed that NOD2 undergoes a 
conformational change during activation, resulting in self-oligomerization, followed by 
recruitment and activation of the serine threonine kinase RICK, which is essential for 
activation of the NF-kappa B and MAPK signaling pathways [26]. It has been 
documented that Rick null cells and Rick knockout mice cannot activate NF-kappa B 
signaling downstream of NOD2, indicating that RICK is a crucial player for the induction 
of inflammatory responses [22], [27].  
Mo et al. in 2012, could demonstrate using purified recombinant NOD2 that NOD2 binds 
directly to muramyl dipeptide and hydrolyzes ATP in vitro [28].  
NOD2 possesses, additional to detecting bacterial pathogens, other vital functions. 
Recently, some studies have suggested that NOD2 signaling is required for the 
regulation of commensal microbiota [29], [30], induction of autophagy [31] and detection 
of single-stranded RNA (ssRNA) viruses. Activation of NOD2 by ssRNA leads to 
interferon regulatory factor 3 (IRF3)-dependent type I IFN secretion and antiviral 
immunity (figure 1.2) [32]. 
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Figure 1.2: According to stimuli NOD2 signaling goes either classical or alternative pathway. Detection of MDP by 
NOD2 forces the signaling toward the classical pathway, which includes recruitment of the kinase RICK then followed 
by the activation of NF-kappa B, which leads to expression of inflammatory cytokines and antimicrobial peptides 
(AMPs). The alternative pathway contains ssRNA-viruses detection by NOD2. The ssRNA-NOD2 complex is 
translocated to mitochondria and interacts with mitochondrial antiviral-signaling protein (MAVS), resulted in activation 
of  interferon regulatory factor 3 (IRF3), which leads to gene expression of IFN. The alternative pathway is RICK-
independent [33]. 
Further studies showed that NOD2 plays a role in adaptive immune responses, in which 
MDP can induce the production of IL-17 from human memory CD4+ T cells, but not 
naive CD4+ T cells, in a NOD2-dependent manner. [34].  
NOD2 comprises 1040 amino-acid residues. It possesses two N-terminal CARD 
domains (CARD1 and CARD2) for protein-protein interaction, one NOD=NACHT domain 
for NTP binding and oligomerization and one C-terminal LRR for detection of pathogens, 
(figure 1.3). 
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Figure 1.3: Schematic representation of NOD2 protein. NOD2 comprises two CARDs domain, for protein-protein 
interaction, NOD=NACHT domain for NTP-binding and oligomerization and LRR domain for MDP binding. 
 
1.1.5 The Caspase-Activating and Recruitment Domain (CARD) 
Hofmann and Bucher in 1997 denoted the name CARD for proteins, which is involved in 
the recruitment of caspases (a family of cysteine proteases that play essential roles in 
apoptosis, necrosis, and inflammation) to the receptor complexes signaling apoptosis 
[35]. CARD proteins are identified as a subfamily of Death Domain (DD) superfamily. DD 
superfamily members play an important role in the intracellular signaling of apoptosis 
and in inflammation. 
DD superfamily covers four subfamilies, Caspase Recruitment Domain (CARD), Death 
Domain (DD), Death Effector Domain (DED) and Pyrin Domain (PYD). The DD 
superfamily is one of the biggest and most studied protein–protein interaction modules. 
The members of this superfamily play an essential role in inflammation, apoptosis, 
immune cell signaling pathways and necrosis [36].  
The functional and structural similarities are the main character for specifying new 
members of DD superfamily. All of the DD superfamily members hold a typical six 
antiparallel alpha-helical bundle, which is named death fold. Members of DD superfamily 
can interact homotypic (within the same subclass to form dimer or trimer) or heterotypic 
(with other members of the superfamily) [37]. 
CARDs are involved in many signaling pathway; like regulation of caspase activity, 
activation of NF-Kappa B during the immune responses or function as intracellular 
caspase inhibitors [38],[39], [40]. 
According to associated domains and functional similarities, CARDs have been 
subdivided into four different subfamilies: (a)  the NBD-CARDs; (b) the coiled-coil 
CARDs; (c) the bipartite CARDs; (d) and the CARD-only proteins. 
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CARDs are small protein of about 10 kDa. The RAIDD CARD was the first CARD 
structure that has been solved. The solution structure of RAIDD CARD consists of six-
helix bundle with three helices vertically stacked on one side and the other three helices 
stacked to form the other side of the molecule. The six antiparallel amphipathic alpha 
helices are arranged firmly around the hydrophobic core of the RAIDD CARD protein 
[38]. 
NLR CARDs (like in NOD2) are involved in the apoptosis, NF-kappa B activation and 
formation of inflammasome [41], [39]. Zhou et al. determined the first NLR CARD 
solution structure (Apaf-I CARD). The solution structure of NOD1 CARD was solved in 
2007 by Manon et al. Both structures (NOD1 CARD and Apaf-I CARD) contain six 
helices and they are similar to other CARDs of known structure (figure 1.4) [42], [43].  
The CARD domains of NOD2 facilitated not only the interactions between activated 
NOD2 and other adaptor proteins but also possibly the homomerization of NOD2 [28].  
  
Figure 1.4: Solution structures of Apa1 CARD and NOD1 CARD presented in ribbon diagram. Both 
structures show the conserved six helices and they have the same orientation. The helices are numbered H1 
to H6 accordingly. Apaf1 CARD PDB ID code is 1C15 and NOD1 CARD PDB ID code is 2B1W. 
Of particular interest, truncated NOD2, short isoform of NOD2 (NOD2-S), consisting of 
the first 126 amino acids of NOD2, is a key regulator of NOD2 activation in the colon. 
NOD2-S is specifically expressed in the human colon and its expression is up-regulated 
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by the expression of cytokine IL-10. Overexpression of NOD2-S down-regulates NOD2-
induced NF-kappa B activation and IL-8 release. Furthermore, NOD2-S also affects the 
maturation and release of pro-IL-1 beta. This cytokine is a crucial player in inflammation, 
angiogenesis and tumors metastasis [44].  
Therefore, it is of interest to set up a protocol for recombinant expression and 
purification of CARD2 to be the basis for functional investigations and structure 
determination. Investigation of this domain in vitro will help us better understanding the 
molecular mechanisms of NOD2.  
 
1.2 Effector Substances of the Innate Immune System: Antimicrobial Peptides  
The Antimicrobial peptides (AMPs) are small molecules, consist of 10 to 50 amino acids 
and are ancient weapons against pathogens. AMPs are a kind of innate immune 
responses against pathogens. They are largely dispersed in nature (in both animal and 
plant kingdom) and they form a distinctive amphipathic shape carrying positive charge 
[45]. Some of AMPs take the amphipathic shape after entering the membrane, like 
cecropin and magainin [46], [47].  
According to their structure, AMPs are subdivided into three families: 1) linear alpha-
helical peptides (cathelicidins), 2) beta-strand peptides connected by disulfide bonds 
(defensins), and 3) loop peptides (bactenecins) (figure 1.6) [48], [49], [50], [51] 
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Figure 1.5: A summary of the structural based families of antimicrobial peptides: A) Alpha-Helical 
peptides, B) Beta-sheet peptides and C) Loop peptides. LL-37 and tritrpticin solution structures 
were solved in the presence of micelles, Protegrin structure was solved in aqueous solution. Blue is 
for positive charged side chain, red is for negative charged side chains and grey is for the remaining 
side chains [51]. 
In addition to killing pathogens, AMPs perform several other functions, such as 
endotoxin neutralizer, chemotaxis factors, induction of reactive oxygen species (ROS) 
formation, induction of wound healing, degranulation of mast cell, help in the 
opsonization process,  complement inhibiter and as a transcriptional factor [52], [53], 
[54]. Therefore, AMPs also called host defense peptides (HDP) [55].  
The major class of AMPs is the defensin family. Defensins are cationic, cysteine rich 
small molecules, which are 3 to 5 kDa and they are expressed in all multicellular 
organisms [56], [57]. The defensins are divided in 3 subfamilies, alpha-defensins, beta-
defensins and theta-defensins. They have some common characters including small 
polypeptide sequences (from 18 to 45 amino acids), formation of 3 intramolecular 
disulfides bonds, lack of posttranslational modifications and turn-linked beta-strands as 
the most dominated features of their tertiary structures [58 440].   
The first human alpha-defensin peptides were isolated and characterized by Ganz et al. 
(1985). They isolated three small peptides (molecular weight < 3,500) from human 
neutrophils and they were denoted as human neutrophil peptide (HNP) because of their 
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expression origin, HNP1-3. Of note, Ganz introduced the name defensins for such 
peptides. They exhibited antimicrobial activities against different strains of bacteria 
(Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli) [59].  
To date, six alpha-defensins in human were identified HNP1-4 in neutrophil [60] and 
defensin 5 and 6 (HD-5 and HD-6) in Paneth cells of the small intestine [61]. Alpha-
defensins possess six cysteine residues, which form three disulfide bonds. The disulfide 
bond pattern (Cys1–Cys6, Cys2–Cys4 and Cys3–Cys5) is the characteristic topology in 
alpha-defensin [62 464]. The overall charge ranges between +2 to +9 [63]. 
The beta-defensins are the second subfamily. In human, four beta-defensin peptides 
have been identified, termed human beta-defensins 1-4 (HBD1-4). Their expression, in 
contrast to alpha-defensin, is not limited to neutrophils and Paneth cells. HBD1-4 are 
broadly expressed in epithelial tissues, including skin, lung, urinary, oral epithelium and 
in neutrophils. Expression of beta-defensins is inducible and is usually up-regulated in 
response to activation of TLRs or in response to production of proinflammatory cytokines 
[64]. HDBs form 3 intramolecular disulfide bonds between Cys1–Cys5, Cys2–Cys4, and 
Cys3–Cys6 [65].  
The third subfamily are the theta-defensins. Theta-defensins were first found in 
monocytes and neutrophils of the rhesus monkey [66]. In human, theta-defensin genes 
were identified; however, the genes contain premature stop codons that terminate their 
translation [67]. Theta-defensins have distinguished features from other types of 
defensin, they form cyclic polypeptide motif [68], and they are microbicidal in the 
occurrence of divalent cations, physiological concentrations of salt and serum [69], [70]. 
In addition to the antimicrobial properties, defensins play a role in immune modulation, 
wound healing and cell migration [71], [55]. 
Various models have been elaborated to explain how AMPs kill bacteria by rupturing 
bacterial membrane (figure 1.6). There are 3 proposed models suggesting that AMPs 
either form ion channels, pores or extensive disruption of the bacterial membrane: The 
first is the barrel-stave, the second is the toroidal (or worm-hole) and the third is the 
carpet model. Each model describes the permeabilization mechanisms of some of AMPs 
[72], [73], [74], [75]. 
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Figure 1.6: Schematic demonstration of the three major models elucidating the mechanisms of 
how AMPs (cationic amphipathic) interact with lipid bilayers and insert into it and result in rupturing 
the membrane. Hydrophilic and hydrophobic are represented in light grey and black respectively 
[76]. 
 
1.2.1 Antimicrobial Peptides of the Horse 
Several antimicrobial peptides (AMPs) of equine have been identified either on mRNA 
and/or on protein level in many tissues of the horse [77]. In equine seven different 
antimicrobial peptide families have been identified and they are 1) Lysozyme [78], 2) 
Cathalicidin [79], 3) Hepcidin [80], 4) Neutrophil antimicrobial peptides [81], 5) NK-lysin 
[82], 6) Psoriasin [83] and 7) Defensin [83].  
 
1.2.1.1 Equine Beta-Defensins  
The first equine defensin (DEFB1) has been characterized by Davis et al [84]. The 
DEFB1 sequence is similar to the human HBD-2. DEFB1 shows the typical beta-
defensin arrangement of disulfide bonds [84]. Many organs express DEFB1 (lung, 
spleen, kidney, liver, small intestine and heart) [84].  
A transcriptional analysis with equine beta-defensin DEFB1 revealed that DEFB2 and 
DEFB3 are copies of DEFB1 [85]. The remaining beta defensins genes (DEFL1, DEFL2, 
DEFL3 and DEFB103) were investigated by Bruhn (Ph.D. thesis) in 2008. 
barrel-stave  toroidal carpet 
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1.2.1.1 Equine Alpha-Defensins 
Based on the sequence information for the equine BAC clone CHORI 241-245H5 
(GenBank® Nucleotide Sequence Database accession number AY170305), Bruhn et al. 
(2007) showed using transcriptional analysis, that an equine small intestine transcript 
might be a potential equine alpha-defensin (DEFA1). The sequence of DEFA1 is 
homologous to Paneth-cell alpha-defensins (HD5) from primates and rodents.  
The peptide of DEFA1 was expressed in E.coli and its biological activity was determined 
against different microorganisms [86]. The mechanism of action of DEFA1 was 
investigated by studying the membrane-permeabilizing activity using viable bacteria and 
membrane models [86].  
The predicted coding region of DEFA1 is 297 nucleotides long. DEFA1 peptide has 98 
amino-acid residues, including the signal peptide and a prodomain. The mature peptide 
consists of 34 amino-acid residues (figure 1.7). DEFA1 is the first equine alpha-defensin, 
which has been characterized in the Laurasiatheria [86].  
 
Figure 1.7: Primary structure of DEFA1. Blue is for the signal sequence, black is for peptide prodomain and red is 
for the mature DEFA1. The active peptide is thirty-four amino-acid residues. It is rich with arginine and contains six 
cysteine residues. 
Further investigations of the repertoire of equine intestinal alpha-defensins using known 
alpha-defensin sequences as matrices revealed that 38 alpha-defensin transcripts are 
present in the equine intestine and at least twenty of them could code functional 
peptides [87]. The biological importance of expressing such a high number of different 
alpha-defensins in the horse intestine is still unclear. The authors claimed that the 
peptides may display various specificities against microorganisms or the intestinal tract 
needs different requirements for antimicrobial peptides through it and this may cause 
spatial expression patterns and sequential expression differences are also possible [87].  
Schlusselhuber et al. (2012) have evaluated the antibiotic activity of DEFA1 peptide in 
vitro against R. equi and its associated pathogens. They found that DEAF1 inhibits the 
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growth of R. equi and S. zooepidemicus and leads to their death by using low 
micromolar concentration. Of note, the bacteria needed much more generations to be 
less sensitive to DEFA1 compared to conventional antibiotics [88].  
DEFA1, as mentioned above, is an equine alpha-defensin. The mature form of DEFA1 
consists of 34 residues, which has a large repertoire and is a promising antibiotic 
peptide against resistant bacteria especially R. equi and S. zooepidemicus.  
Therefore, the determination of DEFA1-structure will help to expose the mechanisms of 
action of this peptide and its structure will be a representative structure for other 
intestinal equine alpha-defensin.  
 
1.3 Nuclear Magnetic Resonance Spectroscopy  
The nuclear magnetic resonance (NMR) spectroscopy was first described in 1946 by 
Bloch and Purcell independently [89], [90]. NMR is a phenomenon of atoms that absorb 
radio-frequency electromagnetic radiation (RF) under the influence of a magnetic field. 
Years later, NMR was introduced as a second method for protein structure 
determination at atomic resolution beside crystallography [91]. 
 
1.3.1 Theory of NMR Spectroscopy 
The idea of the NMR-spectroscopy technique is the usage of the magnetic properties of 
atomic nuclei to get chemical information of the respective nuclei. Only active nuclei are 
interesting from the NMR point of view. The active nuclei are defined as nuclei that need 
to have a property called spin. 
The spin is a quantum mechanical character of atomic nuclei, like electrical charge or 
mass. Spin comes in multiples of 1/2 and can be + or -. From the nuclear spin of an 
atom, the magnetic moment (μ) can be calculated [92].  
Nucleus with spin I=1/2 can have two nuclear spin states of different energy in the 
presence of an applied external magnetic field (two different μ states). Under the 
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influence of a static magnetic field B0, the spin takes two opposite arrangements 
according to the magnetic field axis and processes with respect to that axis. The state 
can be antiparallel to the magnetic field with low energy (α spin state) or parallel with 
high energy (β spin state). The energy difference (∆E) between the spin states is 
proportional to the strength of B0 (figure 1.8).  
  
Figure 1.8: The figure shows the effect of the external magnetic field on nucleus spin states. In 
the presence of an external magnetic field the spins split into high energy state (β spin state) and 
low energy state (α state). The energy difference (∆E) depends on the strength of the magnetic field 
(B0) (modified figure, Lottspeich 1998). 
The circulation of electrons, as a response to B0, produces an induced magnetic field 
(Be) opposing the B0 field. Therefore, the nucleus is slightly shielded by Be field from the 
applied magnetic field B0 and the difference between both magnetic fields (B0–Be) 
represents the actual magnetic field experienced at the nucleus. The mathematical 
relationship between field and frequency is shown by equation 1. 
  ∆E=hν=h(B0-Be)γ    Equation 1 
where: ∆E: Energy difference between spin states, h: Planck's constant, v: 
The frequency of the applied magnetic field, Be: The strength of the 
induced magnetic field, B0: The strength of the external magnetic field and 
γ: Gyromagnetic constant. 
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The precession frequency (v) can be calculated by dividing equation 1 by h. 
  v=(B0-Be)γ     Equation 2 
The frequency of the precession is also called Larmor frequency, which is proportional to 
the strength of the external magnetic field and the gyromagnetic constant of the nucleus. 
In NMR spectroscopy, chemical shifts for nuclei of interest are detected. The chemical 
shift is the frequency of absorption for a nucleus relative to the frequency of absorption 
of a molecular standard like tetramethylsilane (TMS). The chemical shifts of the same 
atoms in one molecule vary due to differences of the chemical environment of the atoms 
in the molecule. Therefore, many shifts appear on the spectrum for atoms of the same 
type. The chemical shift, abbreviated by δ, is expressed in parts per million (ppm) and it 
is calculated from: 
  δ=(v-vTMS)/v0     Equation 3 
- (v-vTMS) is the difference between resonance frequency and that of the 
reference. 
- v0 is the operating frequency of the spectrometer. 
The chemical shifts are the main source of information in NMR-spectra [93].  
Structuring of the amino acid chain by formation of secondary and tertiary structure in 
peptides and proteins is the main factors for occurrence of chemical shifts.  
If a NMR-sample is placed in a homogenous magnetic field, the spins of the atoms split 
according to the occupancy of the energy level of the atoms. The low energy alpha-state 
is favored here. The energy states of the spins can be changed by irradiation of the 
sample using radio frequency-pulses.  
In NMR spectroscopy, sample of condensed matter are investigated (not a free spin with 
a magnetic moment). The sample (like 1H with I=1/2) includes a very large number of 
nuclei with magnetic moments. Therefore, the magnetic moments of the individual 
nuclear spins of a sample can be added up to a total magnetization M0, which can be 
graphically represented as a vector model. In thermodynamic equilibrium, the 
macroscopic M0 is present parallel to the external magnetic field (B0), figure 1.9 left.  
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Figure 1.9: The magnetization can be changed from M0 to My by irradiation the nuclei wit RF 90°-pulses. 
Left: In the thermodynamic equilibrium, the M0 is parallel to B0. Right: RF with 90°-pulse changes the 
direction from M0 to My (modified figure, Lottspeich 1998). 
If the nuclei are irradiated with radio frequency (RF) pulses along the x-axis, this would 
induce a transverse magnetic field B1 in the xy-plane. If the used RF corresponds to the 
resonance frequency of the nuclei, it will follow a rotation of the magnetization M0 to the 
radiation axis in the xy plane. The M0 magnetization can be completely changed to My 
magnetization by using corresponding RF-pulses, (figure 1.9 right). Such pulse is called 
90°-pulse. The change in the total magnetization (from M0 to My) as a result of the 
irradiation by RF leads to the induction of an electric current, which can be detected by 
the inductor of the NMR spectrometer. 
The change to My magnetization is a temporary state. The system attempts to return to 
its initial thermodynamic equilibrium state (M0). This effect is called relaxation, which is 
identified by the longitudinal relaxation time (T1) and the transverse relaxation time (T2). 
The T1 relaxation involves redistributing the spins to reach the thermodynamic 
equilibrium and depends on the external field strength (B0). The transverse relaxation 
time T2 corresponds to decoherence of the transverse spins magnetization (i.e. loss of 
the spin-spin interactions) and be influenced by the molecular weight of the sample. For 
large molecules T2-relaxation is much smaller than T1-relaxation and therefore, T2-
relaxation has a limiting effect on the life time of the NMR-signals. Due to T2-relaxation, 
the NMR-signal is measured as a damped oscillation, which is called free induction 
decay (FID) [92]. 
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Nowadays all modern NMR spectrometers are using the pulse technique. In which, a 
single radio frequency pulse (RF-pulse) or a sequence of RF pulses is sent to a sample 
that is located in a strong magnetic field. The FID signal following a pulse sequence is 
registered as a function of time. By Fourier-transformation, the time signal is transformed 
into a frequency domain signal on the spectrum.  
The simplest and the most common used NMR-experiment is the one-dimensional NMR 
spectroscopy (1D-NMR), figure 1.10.  
   
Figure 1.10: Scheme of a 1D-NMR experiment. The experiment consists of preparation and 
detection phase, which are separated by 90°-pulse. The FID is detected during t1 and transformed 
to frequency domain spectrum (modified figure, Lottspeich 1998).  
The 1D-Fourier-transformation-spetroscopy experiment consists of two phases, the 
preparation and the detection. The simplest of such experiment is when the preparation 
phase is comprised of a single 90°-pulse, which turns the total magnetization from M0 to 
My. In the detection phase, due to T2 relaxation time an electric current is induced and 
detected as FID, which is transformed to frequency domain by Fourier-transformation 
[91]. 
 
1.3.2 Protein NMR Spectroscopy 
NMR spectroscopy (beside crystallography) is a widely used method for three-
dimensional structure determination of proteins. Wüthrich introduced this method to 
study the protein structures in solution [94].  
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To determine a protein structure by NMR spectroscopy, very complex NMR-experiments 
are needed. 1D-NMR spectroscopy provides only general information about the quality 
of the sample. Therefore, 2D and 3D-NMR-experiment are used. The protein size 
determines if the NMR-experiments have to be homonuclear or heteronuclear (i.e. 
labeling the protein sample with C and/or N isotopes) [94]. 
 
1.3.3 Homonuclear Two Dimensional NMR Spectroscopy 
2-dimensional (2D-1H) homonuclear NMR-experiments are used to determine the 
structure of small proteins (<10 kDa). Homonuclear means that magnetization transfer 
occurs between nuclei of the same type. 2D-experiment involves applying a sequence of 
RF-pulses with delay periods in between them. The intensities, frequencies, and timing 
of these pulses distinguish 2D-NMR-experiments from each other.  
Almost all 2D-experiments consist of 4 periods: the preparation period, where a 
magnetization coherence is produced by applying of a set of RF pulses; the evolution 
period, where a determined length of time during which no pulses are applied and the 
spins are allowed to rotate; the mixing period, where the coherence is manipulated by 
another series of pulses into a state which will give an observable signal; and the last 
period is the detection, in which the FID signal is detected and recorded as a function of 
time [92], figure 1.11. The recorded FID is translated to frequency domain, which can be 
seen on the NMR-spectrum.  
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Figure 1.11: 2D-NMR-experiment schemes. On the top is the general schematic of a 2D-NMR-
experiment, it consists of four blocks. Bottom: Schematic representation of the 2D-NOESY-
experiment in which a total of three 90° pulses are irradiated. During the detection phase the FID is 
recorded as a function of time (modified figure, Lottspeich 1998). 
Through repetitions of the experiment, each new repeated experiment will have specific 
evolution time. In these successive experiments, we obtain a series of 1D-spectra, which 
are gradually changing the magnetization that is detected during the evolution phase. A 
further FID-signal appears as a result of increasing the evolution time. The new FID-
signal is translated to frequency domain and the final 2D-spectrum is finished. 
Homonuclear TOCSY (Total Corralation Spectroscopy) and NOESY (Nuclear 
Overhouser Effect Spectroscopy) are the essential 2D-NMR-experiments, which are 
used for homonuclear structure determination. 
In the homonuclear 2D-TOCSY-experiment, the protons are coupled with each other 
over scalar coupling. If magnetization occurs between protons, it appears as a cross-
peak signal. 
The TOCSY-spectrum facilitates the identification of a present amino-acid residue. The 
magnetization goes gradually from a start proton and due to scalar coupling over all the 
protons in this amino-acid residue. Thus, the correlation between the start proton and 
the sequence of all up to three atomic bonds of one amino-acid residue can be 
observed. The correlation of all protons of a residue is defined as the spin system. The 
spin system is a total chemical shift of all protons existing in an amino acid (alpha, beta 
and side chain), figure 1.12.  
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Figure 1.12: Illustration of diagonal signals and cross peaks for a spin system in a TOCSY 
experiment. When nuclei coupled with each other in 2D-NMR experiment, cross-peak signals 
will be detected (red point with black line). Green points represent the resonance of protons on 
the diagonal in the NMR-spectrum. 
In NOESY-experiment, the magnetization transfer bases on the nuclear overhauser 
effect (NOE). The magnetization is transferred over space due to dipolar interaction of 
spins and this is dipolar coupling. This coupling can be detected if the nuclei are closed 
to each other in the space (the distance has to be smaller than 5 Å). The intensity of the 
cross-peak signals is proportional to distance between the protons in the space. The 
relation between intensity of the cross-peak signal and the distance is shown in equation 
4. 
  v (intensity) = 1/r6    Equation 4 
where r is the distance between two nuclei undergoing cross-relaxation.  
The most important information obtained from NOESY-experiment for determination of 
protein structures are depicted in figure 1.13. In NOESY-experiment, the correlation of 
different groups of protons can be detected. On the upper left side of the figure the 
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correlation between amide, aliphatic and alpha-protons can be detected, while at the 
bottom, the correlation between amide protons is observed.  
  
Figure 1.13: Arrangement of magnetization transfer for a 2D-1H-NOESY-experiment in H2O. It shows the 
 correlating chemical shift coordinates to proton-proton magnetization transfer [93]. 
 
1.4 Aim of the Thesis 
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is one of the 
best studied nucleotide-binding oligomerization domain like receptors (NLRs). NOD2 is 
important for innate immune response, autophagy, regulation of commensal microbiota 
and viral immunity [33].  
Furthermore, the short isoform of NOD2 (NOD2-S) plays an important role in the 
regulation of NOD2 activity in the intestine [44]. NOD2 protein contains CARDs domains 
that are predicted to have a role in protein-protein interaction. However homotypic and 
heterotypic interactions of NOD2 CARDs domains are yet to be identified in vitro. 
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DEFA1 is a thirty-four amino acids long equine intestinal alpha-defensin, which has a 
large repertoire in equine intestine and display a broad spectrum against Gram-positive, 
Gram-negative bacteria and against yeast [87].  
DEFA1 becomes interesting after discovery of its potential as a promising antibiotic 
peptide drug especially against R. equi and S. zooepidemicus. Determination of the 
three dimensional structure of DEFA1 peptide will help in illustrating the mechanism of 
action of this peptide and its structure will be the representative structure for other 
equine intestinal alpha-defensins. Of particular interest, DEFA1 will be the first equine 
alpha-defensin structure, which to be determined. 
The specific aims of this thesis are: 
1 To establish a protocol for expression, renaturation and purification of NOD2 
CARD2. Such protocol will enable the production of sufficient amount of a purified 
protein for tertiary structure determination and will also facilitate investigation of 
the homotypic and heterotypic interactions of NOD2 CARD2. 
2 To determine the solution structure of the equine alpha-defensin (DEFA1) and 
compare its structure to structures of other AMPs to better understand its mode of 
action. 
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2 Materials and Methods 
2.1 Cloning of the Human NOD2 CARD2 into pET-32a(+) Expression Vector 
2.1.1 Restriction Digest 
In order to clone the human NOD2 CARD2 as a thioredoxin fusion protein into the pET-
32a(+) bacterial expression vector (Novagen, Merck KGaA, Darmstadt, Germany), the 
human NOD2 CARD2 cDNA (codon-optimized for bacterial expression) was ordered 
from GeneArt (Regensburg, Germany). The cDNA was flanked with KpnI and XhoI 
restriction sites at N- and C-terminus respectively. The human NOD2 CARD2 cDNA 
comprised the His-tag and the enterokinase cleavage site to simplify further working 
steps.  
The size of the cDNA was 369 base pairs (bp) long. Figure 2.1 shows the amino-acid 
sequence of the ordered cDNA. The red letters represent His-tag, green letters 
represent enterokinase cleavage site, blue letters represent amino acid residues derived 
from the expression vector and black letters represent the sequence of human NOD2 
CARD2 
MGSSHHHHHHSSGDDDDKHPARDLQSHRPAIVRRLHSHVENMLDLAWERG               
FVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPL               
ALPLEAATCKKYMAKLR 
Figure 2.1: The amino acid sequence of the human NOD2 CARD2. Blue letters represent the amino acid 
residues derived from pET-32a(+), red is for His-tag, green letters represent the enterokinase cleavage 
site, black letters represent the human NOD2 CARD2. 
To clone the human NOD2 CARD2 cDNA into the bacterial expression vector pET-
32a(+), the vector and human NOD2 CARD2 cDNA were digested using KpnI and XhoI 
restriction enzymes (Fermentas GmbH, Leon-Rot). For restriction digestion 1.5 µg 
human NOD2 CARD2 cDNA and 1.0 µg vector were used and the reaction was done 
using 2X Tango buffer (Fermentas GmbH, Leon-Rot, Gemany). 
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The followings were placed in a clean 1.5 ml tubes:  
    Human NOD2 CARD2  pET-32a(+) 
DNA    15 µl (0.1 µg/µl)   2 µl (0.5 µg/µl) 
Buffer (10X Tango)  5 µl     5 µl 
KpnI    2 µl     2 µl 
XhoI    2 µl     2 µl 
Water    26 µl     39 µl 
Total    50 µl     50 µl 
The reaction mixtures were mixed by tapping, centrifuged in a Eppendorf bench-top 
centrifuge (Eppendorf AG, Hamburg, Germany) and incubated at 37 oC overnight in a 
thermomixer compact (Eppendorf AG, Hamburg, Germany). The mixtures were 
separated on 1% agarose gel (Carl Roth GmbH, Karlsruhe, Germany) in 1X TBE buffer 
for 30 min at 100 V. The electrophoresis was applied using Sub-Cell® GT systems (Bio-
Rad Laboratories, Inc, USA). The agarose gel was stained in 1% ethidium bromide 
(EtBr) bath (Carl Roth GmbH, Karlsruhe, Germany) and the fragments were detected 
under ultraviolet light at 230 nm. The fragments with the corresponding sizes were cut 
and isolated from the agarose gel using gel extraction kit (Nucleo Spin Extract II, 
Macherey-Nagel, Dueren, Germany). The image of the agarose gel was documented 
using gel documentation system (Bio-Rad Laboratories, Inc, USA). 
1% agarose gel 
1g agarose 
100 ml 1x TBA 
1xTris-borate-EDTA (TBE) buffer 
10 g TRIS 
5.5 g boric acid 
4 ml 0.5 M EDTA 
Top up the solution to a final volume of 1000 ml with distilled water (dH2O). 
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2.1.2 Ligation 
Ligation is the process of the formation of phosphodiester bonds in the presence of ATP 
between double- stranded DNAs with 3'-hydroxyl and 5'-phosphate termini [95].  
The digested vector and cDNA were both resuspended in an appropriate volume of 
clean water. The followings were added in a 0.2 ml reaction tube: 
Digested cDNA (insert fragment)     5 µl 
Digested vector (pET-32a(+))     1.5 µl 
T4 ligase (Fermentas GmbH, Leon-Rot, Gemany)  1 µl 10 U/µl 
T4 ligase buffer (Fermentas GmbH, Leon-Rot, Gemany) 2 µl 
Water         10.5 µl 
Total         20 µl 
The reaction mixture was mixed, quick centrifuge and incubated 16 hours at 17 °C. 
 
2.1.3 Transformation of Chemically Competent Escherichia coli (E.coli) strain 
DH5-Alpha 
To produce high amount of expression plasmid for further use, chemically competent 
E.coli strain DH5-alpha cells (Novagen [Merk KGaA], Darmstadt, Germany) were used, 
[96]. The cells were transformed using heat shock transformation method [97].  
To transform the cells, 50 µl of the chemically competent cells were mixed with 10 µl of 
ligation mixture. The cells were incubated on ice for 10 min followed by exposing them to 
42 °C for 2 min. Immediately after 2 min, the cells were incubated on ice for further 5 
min, followed by addition of 1000 μl of pre-wormed LB medium (without antibiotic) and 
incubated at 37 °C for 1 hour. 100 µl of the culture was plated on ampicillin (Carl Roth 
GmbH, Karlsruhe, Germany) (100 μg/ml) containing agar plate. The colonies were 
scored and 2 colonies were selected and further propagated.  
The plasmid DNA was purified using plasmid isolation kit (Nucleo Spin, Plasmid Quick 
Pure, Macherey-Nagel, Dueren, Germany) and sequenced using T7-promoter and T7-
termintor primers by GATC company (GATC, Konstanz , Germany). The two clones 
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showed no mutation. One of these clones was further propagated to produce large 
amount of plasmid. The plasmid was purified using the kit Nucleobond PC 500 
(Nucleobond PC 500, Macherey-Nagel, Dueren, Germany).  
 
2.1.4 PCR Cloning of TEV Protease Cleavage Site 
TEV cleavage site was cloned into the pET-32a(+)-NOD2-CARD2 using Polymerase 
Chain Reaction (PCR) technique [98]. PCR reaction was performed using a site-specific 
forward primer containing the nucleotide sequence of the TEV protease cleavage site 
and a HindIII restriction site as well as a specific reverse primer containing XhoI and a 
stop codon.  
In a PCR tube (0.2 ml) the followings were added:  
DNA template (pET-32(+a)-NOD2-CARD2)   3 µl (10ng/ml) 
Forward primer       1.5 µl (10 pmol/µl) 
Reverse primer       1.5 µl (10 pmol/µl) 
dNTPs (Fermentas GmbH, Leon-Rot, Gemany)  1 µl (10 mmol/µl) 
PCR buffer (Fermentas GmbH, Leon-Rot, Gemany)  5 µl  
pfu-Polymerase (Fermentas GmbH, Leon-Rot, Gemany) 1 µl 
Clean water         37.µl 
Total         50 µl 
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The reaction was then cycled in a Biometra personal cycler (Biometra biomedizinische 
Analytik GmbH Goettingen, Germany) using the following parameters: 
95 °C  120 sec  1x 
95 °C  30 sec  4x 
54 °C  40 sec  4x 
72 °C  60 sec  4x 
95 °C  30 sec  30x 
66 °C  40 sec  30x 
72 °C  60 sec  30x 
72 °C  600 sec  1x 
Next, the PCR mixture was separated on a 1% agarose gel, purified from the gel and 
digested using HindIII and XhoI in Red reaction buffer (Fermentas GmbH, Leon-Rot, 
Gemany). The expression plasmid pET-32a(+) was digested using the same restriction 
enzymes. The digested PCR fragment and the digested vector were isolated from the 
agarose gel and ligated with each other. 
The ligation mixture contained: 
Digested PCR fragment   10 µl 
Digested pET-32a(+)   2 µl 
Buffer (T4 ligase buffer)   2 µl 
T4 ligase     1 µl 
Water      5 µl 
Total      20 µl 
The reaction was performed for 16 hours at 17 °C. Chemically competent E. coli (DH5-
alpha) cells were transformed with 10 µl of ligation mixture and 100 µl of the culture was 
plated on ampicillin containing agar plate. Plasmid DNA was propagated, purified and 
sequenced. One clone, which has the correct sequence were used for protein 
expression.  
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Figure 2.2 shows the construct that was generated for expression of the fusion protein. 
MSDKIIHLTD DSFDTDVLKA DGAILVDFWA EWCGPCKMIA PILDEIADEY QGKLTVAKLN 
IDQNPGTAPK YGIRGIPTLL LFKNGEVAAT KVGALSKGQL KEFLDANLAG SGSGHMHHHH 
HHSSGLVPRG SGMKETAAAK FERQHMDSPD LGTDDDDKAM ADIGSEFELR RQASENLYFQ 
GHPARDLQSH RPAIVRRLHS HVENMLDLAW ERGFVSQYEC DEIRLPIFTP SQRARRLLDL 
ATVKANGLAA FLLQHVQELP VPLALPLEAA TCKKYMAKLR 
Figure 2.2: Protein sequence of TEV-NOD2 CARD2 as a thioredoxin fusion protein (Trx-TEV-NOD2-
CARD2). Red dark colored letters represent the thioredoxin, blue colored letters represent the 
enterokinase cleavage site, green colored letters represent the His-Tag, red colored letters represent TEV 
cleavage site, black bold colored letters represent the human NOD2 CARD2 and black colored letters 
represent the amino acids derived from the expression vector.  
 
2.2 Recombinant Protein Expression 
2.2.1 Protein Expression of Trx-TEV-NOD2 CARD2 Fusion Protein in E. coli Strain 
BL21 (DE3) 
For over-night cultures, 4 ml LB-medium supplemented with 100 μg/ml ampicillin was 
inoculated with a single colony containing the expression plasmid (pET-TEV-NOD2-
CARD2) and incubated at 37 °C with shaking at 220 rpm for 10 hours followed by 
transfer of the starter culture into 50 ml LB-medium supplemented with 100 μg/ml 
ampicillin and incubated at 37 °C with shaking at 220 rpm overnight.  
The overnight culture was diluted 1:200 in 1000 ml fresh LB-medium containing 
antibiotics (100 µg/ml) and was further incubatedc at 37 °C. The protein expression was 
induced by addition of 1 mM isopropyl‐β‐D‐thiogalactopyranosid [IPTG] (Carl Roth 
GmbH, Karlsruhe, Germany) final concentration, when the OD600 reached 0.7. The cells 
were harvested two hours later by centrifugation using Sorvall RC‐5B RSC (Thermo 
Fisher Scientific Inc., MA, USA) at 4°C, 8000 g for 20 min. The Pellets were stored at -
20°C until further use. 
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2.2.2 Isolation of Inclusion Bodies 
The fusion protein (Trx-His-EV-NOD2-CARD2) was expressed in inclusion bodies, so 
the next step was to isolate the inclusion bodies. The pellet gained from the culture was 
thawed and resuspended in 50 mM Tris (Carl Roth GmbH, Karlsruhe, Germany) 
containing 0.1% Tween 20 (Carl Roth GmbH, Karlsruhe, Germany) at pH 8.0. The cells 
were raptured under cooling using sonication (1 min, power 40% and cycle 60%) 
Sonotrode SH213G (Bandelin GmbH & Co. KG, Berlin). The sonication process was 
repeated three times. Next, the suspension was centrifuged at 4 °C, 40000 g for 30 min. 
The washing steps were repeated three times with washing buffer (50 mM Tris, pH 8.0) 
containing 0.1% tween-20 and three times with washing buffer without tween-20. In each 
washing step the pellet was resuspended in the corresponding washing buffer, 
sonicated three times on ice and centrifuged to remove the supernatant. 
 
2.2.3 Purification and Renaturation of the Fusion Protein 
The inclusion bodies were dissolved in 50 mM Tris-HCl, 6 M guanidine hydrochloride 
(GuHCl) (Roche, Mannheim, Germany), pH 8.0 and incubated for three hours at room 
temperature under rotation. The sample was centrifuged at 40000 g for 30 min to 
remove the non-dissolved parts. The supernatant was incubated with pre-equilibrated 
(with 50 mM Tris-HCl, 6 M GuHCl, pH 8.0) Ni2+-agarose matrix (Qiagen, Hillen, 
Germany) for three hours at room temperature under rotation. Next, Ni2+-agarose with 
the adsorbed protein was sediment by centrifugation (Sigma 4-16K, SIGMA 
Laborzentrifugen GmbH, Osterode am Harz, Germany), 500 g, 2 min, at room 
temperature. The sediment was washed four times with 50 mM Tris-HCl, 6 M GuHCl, pH 
8.0 to remove all non-adsorbed proteins. Afterward the protein, which adsorbed to Ni2+-
agarose, was eluted by incubation of the agarose with with 50 mM Tris-HCl, 6 M GuHCl, 
250 mM imidazole (Carl Roth GmbH, Karlsruhe Germany), pH 8.0. 
The Renaturation of the fusion protein was done using dialysis. The fusion protein was 
dialyzed three times, each four hours against 50 mM CAPS (Carl Roth GmbH, 
Karlsruhe, Germany), pH 12 using dialysis membrane ZelluTrans, MWCO: 4000-6000 
Da (Carl Roth GmbH, Karlsruhe, Germany) and the volume ratio of the renaturing buffer 
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to the sample was 1:100. The dialyzed sample was collected and centrifuged to remove 
the precipitated protein and concentrated using Vivaspin 20 concentrators (Sartorius 
Stedim Biotech GmbH, Goettingen, Germany). The renaturing buffer was exchanged to 
50 mM Tris pH 8.0 using NAP columns (GE Healthcare Europe GmbH, Freiburg, 
Germany). 
 
2.2.4 Determination of Protein Concentration 
The simplest way to determine the concentration of a protein is the usage of UV-
spectrophotometry. To use this method, a protein has to contain amino-acid residues 
with aromatic side chain, like phenolic or/and indolic group, which absorb UV-light at 280 
nm. To calculate the concentration of the protein the following equation was used:  
c =A280/(ε280 d) 
c: Protein concentration (mol/l), A280: The absorption at 280 nm, ε280: the absorption 
coefficient (M-1cm-1) and d: The path length of the cuvette (cm).  
The protein concentration of the fusion protein as well as the cleaved form was 
determined using NanoDrop NP-1000 UV–spectrophotometer (PEQLAB Biotechnologie 
GmbH, Erlangen, Germany). The reference was always the protein buffer. For the fusion 
protein the ε280 was 23710 M-1cm–1 and for the cleaved form was 9650 M-1cm–1. The 
extinction coefficient was estimated by the method of Gill and von Hippel [99]. 
 
2.2.5 Discontinuous SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
SDS-PAGE is used to separate protein mixture according to protein size and to display 
the purity of a protein sample. The proteins were separated using stacking and 
separating gel according to Laemmli [100]. The gel electrophoresis was applied using 
Mini-PROTEAN® 3 electrophoresis system from Bio‐Rad (Bio-rad Laboratories GmbH, 
München, Germany) and run at 200 V. The protein samples were dissolved in a 
Laemmli loading buffer, boiled for 5 min by 95 °C and loaded onto a gel. The size of 
protein was estimated by comparing the protein band with the band of unstained protein 
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standard (Fermentas GmbH, St. Leon-Rot, Germany). Next, the gels were stained with 
Coomassie staining solution for 1 h and destained for 1 h.  
Stacking gel (7.5%): 
H2O         2.45 ml 
30% Acrylamide, 0.8% Bisacrylamid (37.5:1)   1.25 ml 
0.5 M Tris-HCl, pH 6.8      1.25 ml 
10% SDS solution       50 μl 
10% Ammonium Peroxydisulphate solution (APS)  50 μl 
N, N, N’, N’- tetramethylethylenediamine (TEMED)  5 μl 
 
Separating gel (15%): 
H2O         2.75 ml 
30% Acrylamide, 0.8% Bisacrylamid (37.5:1)   6 ml 
1.5 M Tris-HCl, pH 8.8      3 ml 
10% SDS solution       120 μl 
10% APS        120 μl 
TEMED        6 μl 
All the chemicals were obtained from Carl Roth (Carl Roth GmbH, Karlsruhe, Germany) 
 
Coomassie stain solution 
10% Methanol 
10% Acetic acid 
0.1% Brilliant Blue G 250 (Cal Roth, Karlsruhe, Germany) 
Destaining solution: 
10% Methanol 
10% Acetic acid 
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2x Laemmli Loading buffer 
Glycerin        2 ml 
10% (w/v) SDS       4 ml 
0.5 M TRIS‐HCl, pH 6,8      2.5 ml 
2.5 ml beta‐Mercaptoethanol for the reducing buffer/2.5 ml water for non-reducing buffer 
ddH2O        0.5 ml 
Bromphenolblau       0.002 mg 
 
2.2.6 Proteolytic Cleavage of Fusion Protein 
After successful renaturation of the fusion protein, the fusion protein could be cleaved by 
enterokinase (Invitrogen GmbH, Karlsruhe, Germany). 1 U enterokinase was used to 
cleave 300 µg fusion protein. The reaction was performed in 50 mM Tris-HCl, pH 8.0, for 
two hours at room temperature under slight rotation.  
 
2.2.7 Gradient Reverse Phase‐High Performance Liquid Chromatography (RP-
HPLC) and Lyophilization 
After cleavage, the protein mixture was separated by RP-HPLC method (880-PU, Jasco 
GmbH, Groß-Umstadt, Germany). The preparative column C18 (VP250/10, Macherey-
Nagel, Düren, Germany) was equilibrated with 100% of HPLC solvent A for 5 min, the 
flow rate was 3.33 ml/min. 1.5 ml (1 mg) of the cleaved fusion protein was acidified using 
6 µl trifluoroacetic acid (TFA) (Sigma Aldrich Chemie GmbH, Steinheim, Germany) then 
centrifuged for 5 min at 20000 g. Afterwards, the supernatant was applied onto the 
column. The gradient elution was performed by increasing the concentration of RP-
HPLC solvent B from 0 to 100% and decreasing solvent A from 100 to 0% within 30 min. 
At the end the column was washed with solvent B for 5 min. The detection was 
performed using a Jasco 875-UV detector (Jasco Labor‐ und Datentechnik GmbH, 
Gross‐Umstadt, Germany) at 280 nm. The fractions of interest were collected and 
lyophilized using Alpha 2‐4 LSC Lyophilizer (Christ GmbH, Osterode, Germany). The 
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lyophilized samples were analyzed by mass spectrometry (MS) to verify their molecular 
weights. 
Solvent A (5% acetonitrile/0.1% (v/v) TFA) 
20 ml acetonitril/0.1% (v/v) TFA (LC-MS Grade, Carl Roth GmbH, Karlsruhe, Germany) 
Top up the to 1000 ml with 0.1% TFA (v/v) water (LC-MS Grade, Carl Roth GmbH, 
Karlsruhe, Germany) 
Solvent B (95% acetonitrile/0.1% (v/v) TFA) 
950 ml acetonitril/0.1% (v/v) TFA 
Add 50 ml 0.1% TFA water (v/v) 
 
2.2.8 Circular Dichroism (CD) Spectroscopy 
CD spectroscopy has a wide range of applications in many different fields. Most notably, 
UV CD spectroscopy is used to investigate the secondary structure of proteins. In the 
far-UV range, the absorption is principally due to the peptide bond, so the different types 
of regular secondary structures found in proteins give rise to characteristic CD-spectra. 
The circular dichroism originates from the differential absorption of right- and left-handed 
circularly polarized components of plane polarized light [101]. The resulting light is 
elliptically polarized, therefore circular dichroism spectra are presented in terms of the 
mean residue ellipticity θ at wavelength λ defined by: 
   ΘλMRW =MRW x θλ /(10 x d x c) 
MRW: The mean residue weight (g mol-1), θ: The observed ellipticity at wavelength λ 
(mgrad), d: The path length (cm) and last c: The protein concentration (g cm-3).  
In addition, the thermal stability of the protein was investigated by keeping the 
wavelength at 222 nm during increasing the temperature gradually (1 °C/min) from 20 
°C to 90 °C. The measurements were done using J-720 spectropolarimeter (Jasco 
GmbH Deutschland, Groß-Umstadt, Germany) and quartz cuvettes (Helma GmbH & Co. 
KG, Müllheim, Gemany). The calibration of the CD-spectropolarimeter was carried out 
according to Chen und Yang [102]. 
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2.2.9 Dynamic Light Scattering 
Dynamic Light Scattering (DLS) is a rapid, non-invasive technique for determination of 
the protein size. In DLS, the scattering intensity fluctuations are monitored and then 
correlated, followed by calculation the size of the particles using the Stokes-Einstein 
equation: 
   RH = kBT/6πηD0 
RH: The particles hydrodynamic radius, kB: Boltzmann’s constant, T: Temperature, η: 
The solvent viscosity, D0: Self-diffusion coefficient [103].  
The protein sample (1 mg/ml) was centrifuged at 20000 g. Sample of 40 µl of the protein 
was transferred into a washed and dried quartz cuvette. The experiment consists of 10 
measurements each with 13 second duration time using Lase-Spectroscatter 201 (RiNA 
GmbH, Berlin, Germany). 
 
2.3 NMR Spectroscopy 
2.3.1 Preparation of Equine Alpha-Defensin (DEFA1) Sample for NMR 
Spectroscopy 
All the experiments, which were necessary to prepare the peptide sample for two-
dimensional NMR experiments (2D-1H-NMR), were done by Dr. Sascha Jung (Group of 
Prof. Dr. Grötzinger, Institute of Biochemistry, University of Kiel). This included, order of 
the synthetic peptide, renaturation, purification using RP-HPLC and characterization of 
the peptide (Ellmann’s test, mass spectrometry and CD-spectroscopy). The NMR 
experiments were done by Prof. Dr. Sönnichsen (Department of Organic Chemistry, 
University of Kiel). 
2.3.2 Performance of 2D-1H Homonuclear TOCSY and NOESY 
To determine the three-dimensional structure of the DEFA1 peptide, two TOCSY and 
four NOESY experiments by different temperatures and mixing times were recorded 
using NMR spectrometer Bruker Avance 600 MHz (Bruker Corp., MA, USA) equipped 
with active shielded Z‐gradient triple resonance cryoprobe.  
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The data sets were processed using the program NMRPipe [104] and NMRView 
software was used for the analysis of the spectra [105]. 
 
2.3.3 Sequence-Specific Assignment 
Sequence-specific assignments are the basis for three-dimensional structure 
determination and other comprehensive studies on dynamics, conformation and function 
by NMR spectroscopy [94.] To perform a sequence-specific assignment of a protein, the 
spin systems for all amino-acid residues of a protein in TOCSY spectrum have to be 
identified based on their specific spin system patterns. The sequence-specific 
assignment of a protein bases on the fact that the distance of the amide proton (HN) of 
one amino acid (i) is shorter than 5 Å to Hα, Hβ and Hγ protons of the precursor amino-
acid residue (i-1). NOESY spectrum contains intraresidual and interresidual signals. By 
comparison of both spectra (TOCSY and NOESY) the interresidual signals can be 
identified.  
From the interresidual signals of NOESY spectrum it is possible to identify the 
neighboring amino acid in the protein. On the resonance frequency of one amide proton 
(HNi) the interresidual cross signals from the side chain of the neighboring amino acid (i-
1) should be visible. 
Using this principle, the amino acid chains of neighboring amino acids for equine 
defensin (DEFA1) were determined. The TOCSY and NOESY spectra (experiment [13], 
experiment [14]) were used to identify the amino acids spin systems and to perform 
sequential assignment. The other spectra were used to verify the results. 
 
2.3.4 Structure Calculation 
The assigned resonance signals from the 2-D homonuclear NOESY spectrum were 
converted in proton-proton distances using NMRViewJ. The distances between the 
protons were calculated using the cross-peak signal intensities. The smallest distance 
was set to 1.8 A° and the biggest to 5 A°. The determined distances were calibrated 
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using the r6 function; r refers to the distance between two protons. The average 
intensities of all the NOEs were equated to a distance of 2.8 A° and the tolerance was 
0.125 times to the respective distance square. The intensity of the methyl group was 
halved. The distances information’s were used for structure calculation using the 
program CYANA 2.1 [106]. The disulfide bonds were set between C1-C6, C2-C4 and 
C3-C5 and 18 additional distances have been added to the calculation to define the 
three disulfide bonds of the peptide. For the S-S bound, the following was applied 2.0 ≤ 
d(Siγ, Sjγ) ≤ 2.1 Å; 3.0 ≤ d(Ciβ, Sjγ) ≤ 3.1 Å; 3.0 ≤ d(Siγ, Cjβ) ≤ 3.1 Å.  
The structures were represented using MOLMOL [107] and GRASP2 programs [108]. 
The analysis of the dihedral angles and the Ramachandran plot were done using 
CYANA 2.1 program. The electrostatic surface potential was represented using 
GRASP2 program. 
100 structures were calculated using CYANA program. From the 100 calculated 
structures, 10 structures with the lowest target functions were selected. 
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3 Results 
3.1 NOD2 CARD2 
In the present work, a protocol for NOD2 CARD2 expression, renaturation and 
purification was established.  
 
3.1.1 Protein Expression 
Expression of TEV-NOD2 CARD2 fusion protein in the chemically competent E.coli 
strain BL21 (DE3), using the expression vector pET-32a(+) containing N-terminal 
thioredoxin (Trx)-, His-tag and enterokinase cleavage site, was induced by 1 mM IPTG 
(final concentration and OD600 reaching 0.7) in LB medium. SDS-PAGE analysis 
detected a band with a molecular weight between 25 and 35 kDa (figure 3.1 (A)), which 
corresponds to the expected molecular weight of the fusion protein (31 kDa). Various 
expression times were tested in order to maximize the expression of the fusion protein. 
The data showed equal amount of protein after 2 and 16 hours of expression, indicating 
that the amount of protein does not increase with longer expression time (figure 3.1(A)). 
To characterize the solubility of the expressed fusion protein, the bacterial cells were 
disrupted in 50 mM Tris, pH 8.0 by sonication. Then soluble and insoluble materials 
were separated by centrifugation and analyzed by SDS-PAGE. The data demonstrated 
that the fusion protein was expressed as unfolded aggregates in inclusion bodies rather 
than as a soluble protein (figure 3.1(B)). 
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Figure 3.1: SDS-PAGE analysis of the expressed fusion protein in E.coli strain BL 21 
(DE3). A) The SDS-gel electrophoresis separation of the expressed fusion protein in 
bacteria before induction (0), 2 hours (T1) and 16 hours after induction (T2), showing that 
longer expression time does not increase the amount of the expressed fusion protein. B) 
SDS-gel shows that the fusion protein is expressed as aggregated unfolded protein in 
inclusion bodies, but not in a soluble form. S: Cell supernatant, P: Cell debris, M indicates 
the protein molecular weight standard (kDa). Black arrows indicate the expressed fusion 
protein. 
 
3.1.3 Purification of the Trx-TEV-NOD2 CARD2 Using Ni2+-NTA Agarose Beads 
under Denaturing Condition. 
In order to purify the expressed fusion protein, bacterial cells were collected after 2 
hours of induction, centrifuged and disrupted by sonication in an ice bath. Then, 
inclusion bodies (IBs) were isolated by centrifugation and washed six times with the 
corresponding washing buffers under sonication. The washed IBs were dissolved in a 
denaturing buffer (50 mM Tris, 6 M GuHCl, pH 8.0), followed by incubation with pre-
equilibrated Ni2+-NTA agarose beads at RT for three hours. The beads were washed 
four times with the denaturing buffer, followed by an elution buffer (50 mM Tris, 6 M 
GuHCl, 250 mM imidazole, pH 8.0). Samples of the IBs were collected at each step 
during this purification process, including before loading (B); flow through (FT); washing 
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supernatants (W1 and W4); and elution fractions (E1 and E2). The collected samples 
were then analyzed by SDS-PAGE (figure 3.2 (A)), which demonstrated that the fusion 
protein is present in significantly larger quantities in E1 and E2 than in the original 
sample (B) before purification as shown in figure 3.2 (A). To ensure the sensitivity and 
the specificity of the purification process, EI and E2 fractions were combined, diluted 10 
times and reexamined on an SDS-PAGE. As shown in figure 3.2 (B), the combined 
diluted E1 and E2 fractions (E1+2) shows only one band corresponding with the 
predicted size of the fusion protein, indicating an overloading of the purified protein in E1 
and E2 fractions (figure 3.2 (A)), beyond the capacity of the SDS-PAGE gel, rather than 
the presence of impure proteins. Therefore, the presence of a significant amount of the 
fusion protein in the flow through (FT) sample as well as some traces in the supernatant 
of W1 and W4 samples (Figure 3.2 (A)) suggested that the quantity of the fusion protein 
is exceeding the binding capacity of the beads. Thus, the data suggest that the fusion 
protein is almost pure.  
  
Figure 3.2: SDS-PAGE analysis of the purified Trx-TEV-NOD2 CARD2 fusion protein. A) 
Samples of solubilized IBs before loading (B), flow through (FT), washing steps (W) and 
elution steps (E) were analyzed. The SDS-gel capacity was overloaded in E1 and E2 (elution 
lines). B). the elution fractions (E1+2) were combined together, diluted 10 times and 
reanalyzed. The E1+2 fraction showed that the fusion protein is almost pure. 
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3.1.5 Renaturation of the Trx-TEV-NOD2 CARD2 Fusion Protein 
The purified fusion protein was renaturated by dialysis, followed by a rapid buffer 
exchange. In particular, the fusion protein was dialyzed against 50 mM CAPS, pH 12, 
three times, four hours each and concentrated, followed by changing the dialysis buffer 
to 50 mM Tris, pH 8. The purity of the fusion protein (FP) was assessed on SDS-PAGE 
under reducing (FPR) and non-reducing conditions (FPnonR). The size of the fusion 
protein was not affected by the non-reducing Laemmli buffer treatment (figure 3.3 the 
lines (FPnonR)). As shown in figure 3.3, the data suggest that the fusion protein is almost 
pure and did not form oligomers though disulfide bond formation. 
   
Figure 3.3: SDS-PAGE analysis of the fusion protein after renaturation. The Fusion 
protein was next refolded by dialysis, followed by rapid buffer exchange. The fusion 
protein (FP) was analyzed on SDS-PAGE under reducing (FPR) and under non-reducing 
conditions (FPnonR), M: Protein standard, black arrows indicate the fusion protein. 
 
3.1.6 Dynamic Light Scattering (DLS) of Fusion Protein 
DLS was used to precisely determine the size of the renatured fusion protein, where 40 
µl of the renatured fusion protein (1 mg/ml) was measured 10 times, 13 seconds each at 
room temperature. As shown in figure 3.4, the blue dots represent the radius of the 
protein in relation to a particular measurement time. The number of dots in each 
measurement represents the number of the present species in the protein solution. The 
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data demonstrated that the radius of the fusion protein was 12 nm and the fusion protein 
is present in a monodisperse form. The size of the radius (12 nm) is larger than the 
expected size for a 31 kDa protein according to the control experiment (albumin 1 
mg/ml, 66 kDa). The radius of albumin under the same experiment conditions was 5 nm 
(data not shown). The data suggest that the renatured fusion protein is present in the 
buffer system as small monodisperse soluble oligomers. Unfortunately, the size of the 
renatured protein could not be confirmed using size-exclusion chromatography (SEC) 
due to a high hydrophobic affinity of the fusion protein to the SEC matrix (data not 
shown). 
   
Figure 3.4: The radius of the renatured fusion protein was determined using 
dynamic light scattering (DLS). Sample of 40 µl fusion protein (1 mg/ml) was 
measured in DLS. The radius (Y-axis) was plotted against the time (X-axis). The 
plot demonstrates the radius and the monodispersity of the fusion protein. 
 
3.1.7 Cleavage of the Fusion Protein 
After purifying and determining the size of the fusion protein, we set out to purify the 
protein of interest (NOD2 CARD2). The fusion protein has two cleavage sites, a TEV 
and enterokinase (figure 2.2). The fusion protein in its native form was cleaved by the 
TEV protease. Aliquots of the cleavage mixtures, after 2 hours of incubation time, were 
centrifuged to separate soluble and non-soluble materials, followed by analyzing the 
fractions by SDS-PAGE under non-reducing conditions. The untreated fusion protein 
was used as a reference to estimate the cleavage efficiency. The TEV protease cleaved 
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the fusion protein into a 20 kDa fusion tag and 11.4 kDa NOD2 CARD2. SDS-gel 
analysis of the soluble fraction detected two bands (figure 3.5 (A)). The lower band, 
according to the protein standard, is about 20 kDa and the upper band about 31 kDa. 
The 20 kDa and 31 kDa bands contain the fusion tag and the uncleaved fusion protein, 
respectively. NOD2 CARD2 protein (11.4 kDa) was not detected.  
An SDS-PAGE analysis of the insoluble fraction of the cleavage mixture is shown in 
figure 3.5 (B). The gel electrophoresis separation of the sample resulted in three protein 
bands. The lowest band is about 12 kDa, which probably contains NOD2 CARD2 
protein. The upper two bands contain the fusion tag and the fusion protein. The upper 
band (31 kDa), which represents the uncleaved fusion protein in figure 3.5 B, is very 
small compared to the fusion protein before cleavage, while the lowest band (12 kDa), 
which contains NOD2 CARD2 protein, appears large and intense. The 20 kDa band in 
figure 3.5 B, which contains the fusion tag, is very weak compared to the fusion tag band 
in figure 3.5 A. This data suggest that the cleavage of the fusion tag by TEV protease 
induces instability in NOD2 CARD2 and led to precipitation of the protein, which is 
present in the insoluble fraction. Thus, the data demonstrate that almost all of the fusion 
protein was cleaved by TEV protease and NOD2 CARD2 is stable in the buffer system 
as a fusion protein.  
Many experiments have been attempted to increase the stability of the cleaved NOD2 
CARD2 by changing the cleavage reaction conditions, however; NOD2 CARD2 remains 
unstable after cleavage of the fusion tag (data not shown). 
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Figure 3.5: SDS-PAGE analysis of proteolytic cleavage of the fusion protein (31 kDa) by 
the TEV protease. Sample of 300 µg of fusion protein was used. The sample was 
incubated with 9 µg TEV protease for 2 hours at room temperature. Sample of 20 µl was 
taken from the reaction mixture, centrifuged and the soluble fraction was analyzed by 
SDS-PAGE under non-reducing condition (A) and the insoluble fraction as well (B). M: 
Protein marker, B: The fusion protein before cleavage, S: The soluble material, P: The 
insoluble material. 
Therefore, the renatured fusion protein was cleaved by enterokinase. The cleavage 
mixture was centrifuged and the supernatant was analyzed by SDS-PAGE under non-
reducing condition. The endoprotease cleaved the fusion protein into a 13.9 kDa NOD2 
CARD2 and a 17.1 kDa fusion tag. Samples of fusion protein before cleavage (as a 
reference) and the cleavage mixture, 2 hours after of cleavage time, were analyzed by 
SDS-PAGE (figure 3.6). Gel electrophoresis of the cleavage mixture detected three 
protein bands (figure 3.2 lane S). The lowest protein band is about 14 kDa and it 
contains NOD2 CARD2. The remaining two upper bands contain the fusion tag (about 
17 kDa) and the uncleaved fusion protein (31 kDa). After cleavage, NOD2 CARD2, non-
cleaved fusion protein and fusion tag are present in the soluble fraction, indicating that 
cleavage of the fusion tag by the enterkinase does not alter the stability of NOD2 
CARD2, in contrast to the cleavage of the fusion protein by TEV protease. However, 
NOD2 CARD2 fragment resulting from the endoprotease cleavage contains 23 
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additional amino-acid residues upstream of its N-terminus and therefore; was donated 
as 23aa-NOD2 CARD2. The data show that enterokinase cleavage of the fusion protein 
resulted in a stable 23aa-NOD2 CARD2. However; the cleavage efficiency of the 
enterokinase was not 100 %. Experiments to increase the efficiency of the enterokinase 
cleavage by changing the reaction conditions have been attempted but the cleavage 
efficiency did not change (data not shown).  
   
Figure 3.6: SDS-PAGE analysis of the proteolytic cleavage of the renatured fusion 
protein by the enterokinase. Sample of 300 µg fusion protein was incubated with 1 U of 
the enterokinase for 2 hours at room temperature. Sample of 20 µl of the reaction mixture 
was centrifuged and analyzed by SDS-PAGE under non-reducing condition. B: The fusion 
protein before cleavage, S: Sample of cleavage mixture, M: protein standard. 
 
3.1.8 Purification of the 23aa-NOD2 CARD2 
In order to purify the 23aa-NOD2 CARD2, the fusion protein solution after proteolytic 
cleavage was fractionated using reversed phase high performance liquid 
chromatography (RP-HPLC) (figure 3.7). RP-HPLC chromatogram showed two 
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interesting fractions (fraction 1 and 2). These two fractions were collected, lyophilized 
and characterized by mass spectrometry.  
Mass spectrometry analysis of fraction 1, eluted at 21.8 min, detected a protein with a 
mass of 13965 Da, which corresponds to the expected molecular weight of the 23aa-
NOD2 CARD2 (figure 3.8).  
 
Figure 3.7: Reversed phase high performance liquid chromatography (RP-HPLC) 
purification chromatogram of the 23aa-NOD2 CARD2. The cleavage reaction mixture was 
purified by RP-HPLC. Black line: Elution run, red line: Acetonitrile gradient. Both fractions 
were lyophilized and analyzed by mass spectrometry. 
The purity of the purified lyophilized 23aa-NOD2 CRAD2 was analyzed by SDS-PAGE 
under non-reducing conditions (figure 3.9). Gel electrophoresis detected only one 14 
kDa protein band, which did not form oligomers through formation of disulfide bridges. 
The data demonstrate that the 23aa-NOD2 CARD2 could be purified using RP-HPLC 
and the protein is pure.  
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Figure 3.8: Mass spectrometry analysis of the fraction 1 eluted at 21.8 min. The mass of 23aa-
NOD2 CARD2 was determined by MALDI-TOF mass spectrometry. Fraction 1 contains the 23aa-
NOD2 CARD2 protein. The mass to charge was represented as m/z. 
   
Figure 3.9: SDS-PAGE analysis of the 23aa-NOD2 CARD2 from fraction 1. The SDS-gel was 
performed under non-reducing condition. The arrow indicates the 23aa-NOD2 CARD2 protein. M: 
Protein marker, F1: RP-HPLC fraction 1 at 21.8 min. 
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3.1.9 Determination of the Secondary Structure of the 23-NOD2 CARD2 Using CD-
spectroscopy 
To further characterize the 23aa-NOD2 CARD2, its secondary structure was 
investigated by far-UV CD-spectroscopy.  
The lyophilized 23aa-NOD2 CARD2 was reconstituted in 50 mM phosphate, pH 4.6 and 
its secondary structure and thermal stability were studied. Figure 3.10 demonstrated the 
CD-spectrum of the 23aa-NOD2 CARD2 protein at room temperature. The curve shape 
is similar to a CD-spectrum of alpha-helical proteins, which are characterized by two 
minima, at 208 and 222 nm, followed by an increase of the ellipticity at 205 nm.  
In addition, the thermal stability of the 23aa-NOD2 CARD2 was studied. The alteration of 
the signal intensity at 222 nm was observed at increasing temperatures. The signal 
intensity (Y-axis) was plotted against the temperature (X-axis). The curve, shown in 
figure 3.11, displays the heat stability spectrum of the 23aa-NOD2 CARD2. The intensity 
of the signal remains constant until the temperature reaches 55 °C and then the intensity 
starts to decrease until the temperature reaches 80 °C. The alteration of the CD-signal 
at 222 nm indicates that the secondary structure elements, alpha-helices in the case of 
23aa-NOD2 CARD2, are lost under the influence of increasing temperature.  
To investigate the reversibility of the denaturing process, the protein was gradually 
heated and cooled. The CD-spectra, which were recorded during heating and cooling 
phases, indicate that the heat denaturing process is not reversible; because the signal at 
222 nm did not increase during the cooling phase (data not shown). 
To further investigate the heating effect on the 23aa-NOD2 CARD2, two different CD-
spectra were recorded, the first one at 20 °C and second at 90 °C. In comparison to the 
spectrum at 20 °C, the spectrum at 90 °C showed less intensity and lost the minima. 
The data show that the purified 23aa-NOD2 CARD2 is refolded, forms alpha-helices as 
the main secondary structures, heat sensitive and the thermal unfolding process is not 
reversible.  
Effect of heat on the protein was further investigated by DLS. The protein was heated for 
a short time and measured (see section 3.1.10).  
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Figure 3.10: CD-spectrum of the 23aa-NOD2 CARD2, reconstituted in 50 mM sodium 
phosphate, pH 4.6, at room temperature. The spectrum shows a typical alpha-helical 
structure. The spectrum shows tow minima at 222 and 208 nm respectively and 
increasing of the intensity at 205 nm.  
  
Figure 3.11: Investigation of thermal stability of 23aa-NOD2 CARD2. The CD-spectrum 
shows the signal intensity of the protein at 222 nm in relation to temperature. The 
temperature was gradually increased (1 °C/min) from 20 °C to 90 °C.  
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Figure 3.12:  CD-spectra of the 23aa-NOD2 CARD2, reconstituted in in 50 mM 
phosphate, pH 4.6 before and after thermal treatment. Black line: CD-spectrum of the 
23aa-NOD2 CARD2 at room temperature and red line is for the CD-spectrum at 90 °C. 
 
3.1.10 Dynamic Light Scattering of 23aa-NOD2 CARD2 
The 23aa-NOD2 CARD2 was further characterized by determining its size by DLS. The 
radius plot, shown in figure 3.13, represents the radius of the protein in 10 different 
measurements. The blue dots show the radius in relation to the time of measurement 
and the number of present species in the solution. The size of the dots represents the 
dominancy of the recorded species to other species in a particular measurement; where 
large dots represent large amount of particular species and small dots represent small 
amount in the solution. The most dominant species is that with 17 nm radius. Of note, 
other species are present in small amounts. The data demonstrate that the radius of 
23aa-NOD2 CARD2 is 17 nm and this species is mostly present in the solution.  
The thermal effect on 23aa-NOD2 CARD2 was investigated. The protein was heated 
and measured in DLS under the same experimental conditions. Figure 3.14 shows that 
heating of the protein sample for a short time led to formation of big oligomers. The size 
of the protein after treatment increased dramatically from 17 nm to 90 nm. The same 
phenomenon was observed as 150 mM NaCl was added to 23aa-NOD2 CARD2 in 
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phosphate buffer (figure 3.15). Compared to heat treatment the monodispersity of 23aa-
NOD2 CARD2 is almost lost. The data show that the protein is heat and salt sensitive. 
Interestingly, the protein remained almost monodisperse at least after heat treatment 
and soluble after both treatments. 
   
Figure 3.13:  The hydrodynamic radius of the 23aa-NOD2 CARD2 was 
determined using dynamic light scattering (DLS). The Radius plot shows the 
dispersity and the size of the radius of 23aa-NOD2 CARD2.  
   
Figure 3.14: The effect of heat on 23aa-NOD2 CARD2 size. The protein was 
heated and measured in DLS. The radius plot displays the size and dispersity of 
the protein. 
Results      51 
 
     
Figure 3.15: The effect of NaCl on 23aa-NOD2 CARD2 size. NaCl (150 mM) was 
added to protein in phosphate and measured in DLS. The radius plot displays the 
size and dispersity of the protein. 
 
3.1.11 NMR-Spectroscopy of the 23aa-CARD2 NOD2 
The goal was to prepare a NOD2 CARD2 protein sample, which is suitable for NMR 
experiments, in order to determine the 3D-structure. 1D-1H-experiment gives information 
about the suitability of the sample for NMR-spectroscopy. The most important obtained 
information from a 1D-1H-experiment is the shape and dispersion of the proton signals in 
the spectrum. The both parameters are determining the suitability of a given sample for 
NMR. The 1D-1H-NMR spectrum, shown in figure 3.14, represents 1D-1H-NMR 
experiment of 23aa-NOD2 CARD2. The spectrum shows that the dispersion of the 
backbone amide and aliphatic protons is very low and the sample in its actual status is 
not suitable for NMR experiments. 
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Figure 3.16: A 1D-1H-NMR experiment of the 23aa-NOD2 CARD2. The spectrum shows the 
dispersion of the backbone HN and the aliphatic protons.  
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3.2 Determination of the Three-Dimensional Structure of Equine DEFA1 
DEFA1 was identified and characterized by Bruhn et al [86]. In the present work, the 
three dimensional structure of DEFA1 peptide will be determined using 2D-1H-
homonuclear NMR-spectroscopy.  
The synthetic DEFA1 was refolded, purified and reconstituted in 20 mM phosphate at pH 
5.7, the concentration of the peptide sample for NMR-spectroscopy was 0.3 mM.  
Homonuclear TOCSY and NOSEY experiments were recorded at different temperatures 
and mixing times.  
The structure was determined using spectra, which have low signal-to-noise ratio and a 
high number of signals. The TOCSY-spectrum was recorded at 278 K with a mixing time 
of 60 ms and the NOESY-spectrum at 278 K with 200 ms 
 
3.2.1 Identification of the Spin Systems of DEFA1 
The first step to determine the solution structure of a peptide is to identify the amino-acid 
spin systems. 2D-1H homonuclear TOCSY experiments served to identify the amino-
acid spin systems.  
In a TOCSY experiment all protons of a spin system correlate via scalar couplings. 
Using characteristic spin system pattern it is possible to identify the related amino-acid 
residue. TOCSY-spectrum displays only the intraresidual signals; therefore it also serves 
to distinguish the interresidual from intraresidual resonance signals in 2D-1H 
homonuclear NOESY-spectrum. 
The TOCSY-spectrum of DEFA1 peptide at 278 K and 60 ms mixing time is shown in 
figure 3.17. The rectangles represent the type of protons that correlate with each other. 
The backbone amide proton of an amino-acid residue correlates with the present alpha-, 
beta-, gamma- or delta-protons of its own residue. According to the type of correlated 
protons the location of the cross peaks (resonance) on the spectrum will differ. 
Therefore, the correlation of aromatic protons can be seen between 6 and 7 ppm, while 
the amide with alpha-protons or the amide with aliphatic proton can be seen between 7 
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and 10 ppm. The parallel vertical signal rows on the upper left side of the figure 3.15 
represent the correlated protons resonance signals of the amino-acid residues of 
DEFA1.  
The TOCSY-spectrum also enables the identification of some of the amino-acid residues 
according to their characteristic spin system patterns, including leucine, isoleucine, 
glycine, threonine, lysine and alanine. The spin system patterns of the remaining amino-
acid residues are similar and additional information is needed to identify them.  
DEFA1 comprises 34 residues. Out of the 34 spin system 33 could be identified. Alanine 
7 is the only residue that was identified from the TOCSY-spectrum due to its 
characteristic spin system pattern.  
 
Figure 3.17: 1H-Homonuclear 2D-TOCSY-spectrum of DEFA1. The resonance signals (black dots) are 
resulted from scalar coupling of the all amino-acid residues protons of DEFA1. The present spin systems 
(the upper left blue square) resulted from the correlation of the backbone amide protons with the side 
chain protons. This spectrum was recorded at 278 K and with 60 ms mixing time. 
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To illustrate the identification of the spin systems of DEFA1 amino-acid residues, glycine 
13 spin system is shown in figure 3.18. The figure shows the unambiguous spin system 
pattern of glycine 13. It has only 2 alpha-protons and due to the strong coupling between 
them, both protons can be seen in TOCSY-spectrum. The resonance signals show the 
correlation between the amide proton and the alpha-protons of glycine, i.e., the 
correlation between Hα1(i)‐HN(i) and Hα2(i)‐HN(i).  
The identification of a spin system is based on the difference in chemical shifts of its 
protons. DEFA1 peptide contains 34 amino-acid residues. Seven of its amino-acid 
residues are present only one time in the peptide, including alanine, glutamate, 
aspartate, glutamine, histidine, leucine and tyrosine. Otherwise the remaining residues 
appear at least two times. Alanine is the only residue, which could be unambiguously 
identified using the TOCSY-spectrum. 
   
Figure 3.18: The spin system pattern of the L-glycine. On the left side is a section from 
60 ms TOCSY spectrum of DEFA1. It shows the spin system pattern of the glycine 13. On 
the right side is the graphical presentation of a typical spin system pattern of L-glycine. 
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3.2.2 Homonuclear Sequential Assignment 
The next step after identification of the spin systems of DEFA1 amino-acid residues is to 
determine their location in the sequence (sequential assignment). The 2D-NOESY-
spectrum was used to do so, where all protons correlate via dipolar coupling, i.e. a 
NOESY-experiment detects the intraresidual signals of a residue (its own protons 
resonances) and interresidual (not own protons resonances). However, the interresidual 
signals can be only detected if the distances between the protons are ≤ 5 Å.  The 
interresidual signals can be seen because of the spatial proximity (due to direct 
neighboring of two amino acids and folding of the peptide). 
A NOESY-spectrum with 200 ms mixing time was used to sequentially assign the amino-
acid residues of DEFA1 and is shown in figure 3.19. The spectrum shows the proton 
resonances, which correlate via dipolar coupling. The overlay of both spectra (TOCSY 
and NOESY) (figure 3.20) illustrates the difference in the number of resonance signals. 
The black resonances are much more compared to red resonances due to interresidual 
resononce. 
 
Figure 3.19: Homonuclear 2D-NOESY spectrum of DEFA1 with 200 ms mixing time. It shows the 
resonance signals due to dipolar interaction of protons, which are less than 5 Å apart.  
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Figure 3.20: Overlay of a section from DEFA1 NOESY- and TOCSY-spectrum. The figure 
shows the overlay of NOESY (black dots) and TOCSY resonance signals (red dots). The 
red dots refer to intraresidual and black to interresidual signals. The NOESY- contains 
much more resonance signals than TOCSY-spectrum. 
As was mentioned earlier, 33 out of 34 spin systems could be identified. The first step to 
make a sequential assignment is the identification of amino-acid residues, which have a 
unique spin system pattern. After the identification of the interresidual resonance signals 
on these spin systems, it will help in the identification of the neighboring amino-acid 
residues. Usually, the distance between the protons (Hα, Hβ, HN,…) of an amino-acid 
residue (i) and the amide proton of the residue (i+1) is smaller than 5 Å, and due to 
dipolar coupling, interresidual resonance signals can be detected on the vertical 
frequency axis of the amide proton of the amino acid (i+1) beside its own intraresidual 
signals.  
Figure 3.21 shows an example for the sequential assignment of the neighboring amino-
acid residues through identification of the interresidual signals in NOESY-spectrum. The 
figure displays the sequential assignment of arginine 6 to isoleucine 9.  
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Alanine 7 and tryptophan 8 contain besides their intraresidual signals the interresidual 
Hα protons from each preceding amino acid. Isoleucine 9 contains only the Hβ proton 
from the preceding tryptophan 8.  
 
Figure 3.21: Homonuclear sequential assignment strategy of DEFA1 using NOESY-experiment. 
Four strips from NOESY-spectrum show the spin system of the amino-acid residues arginine 6 to 
isoleucine 9. The arrows point out the interresidual signals from the neighboring amino acids. 
Using this strategy almost all the amino acid spin systems of DEFA1 were identified. The strips 
were taken from the NOESY-spectrum with 200 ms mixing time. 
Using this strategy, 30 out of 34 amino-acid residues were identified and sequential 
assigned. The residues are serine 1 to lysine 19, serine 25 to arginine 34 and glutamine 
23. The remaining four amino acids (Cys20, Ile21, Asp22 and Lys24) could not be 
identified. 
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3.2.3 The Secondary Structure Elements of DEFA1 
After sequential assignment of the spin systems and identification of the protons 
resonances in the NOESY-spectrum, the existing secondary structure elements in 
DEFA1 could be estimated.  
The formation of secondary structural motives is depended on the existence of contacts 
between protons of neighboring amino acids or between amino acids, which are over an 
average distance of up to four amino acid residues, namely short range and medium 
range contacts, respectively.  
A beta-sheet structure is characterized by the presence of a correlation between HN(i)-
HN(i+1) and Hα(i)‐HN(i+1) of the neighboring amino-acid residues in the NOESY-
spectrum. Figure 3.22 shows the sequential and medium range contacts obtained from a 
2D-homonuclear NOESY-spectrum. The bars represent the protons contacts and the 
thickness of the bars represents the correlation strength. Thick bars represent strong 
coupling while thin bars represent weak coupling. The sequential contacts between the 
protons HN(i)-HN(i+1) and Hα(i)‐HN(i+1) show a typical beta-sheet signal pattern. Medium 
rage contacts, which are typical for alpha-helical structure, were not detected. 
  
Figure 3.22: Sequential plot of the identified contacts. The figure shows the short and medium 
range contacts obtained from the homonuclear 2D-NOESY-spectrum of DEFA1. These contacts 
define the secondary structure of DEFA1. The amino acid sequence of DEFA1 is represented at 
the top. The bars represent the correlation between neighboring protons HN(i)-HN(i+1) and Hα(i)‐
HN(i+1). The thickness of the bars corresponds to the intensities of the detected resonance 
signals.  
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3.2.4 The Tertiary Structure of DEFA1 
Secondary structural motives depends on the presence of sequential and medium range 
contacts, while the long range contacts are crucial for the tertiary structure.  
The long range contacts of DEFA1 residues in the NOSEY-spectrum were assigned. An 
example of the correlation between protons over a long distance is shown in figure 3.23. 
The figure shows the coupling of alpha-protons and amide protons of 4 amino-acid 
residues of DEFA1. The amide proton (HN) of arginine 15 correlates with the alpha-
proton (Hα) of arginine 33 and the HN of cysteine 32 correlates with the Hα of histidine 16 
(represented by the dotted arrows and the circle, respectively. 
  
Figure 3.23: NOESY-spectrum for the long range contacts in DEFA1. The section shows the 
correlation between the amide proton of cysteine 32 (HN) and the alpha-proton of histidine 16 (Hα) 
as well as the amide proton of the arginine 15 and the alpha-proton of arginine 33. The vertical 
dotted lines represents the spin systems of the corresponded amino acids and the dotted arrows 
and the circle represent the long range distance coupling. 
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Figure 3.24 represents the distance restraints, which were used for the calculation of 
DEFA1 structure. The distance restraints were divided into 4 groups and schematically 
shown as bar for each amino-acid residue. The division into groups was based on the 
distance of the respective contacts to each other. These groups included the 
intraresidual, sequential, medium and long range contacts.  
  
Figure 3.24: Distribution of the distance restraints over DEFA1 peptide sequence. The distance 
restraints for each amino-acid residue were divided into groups according to the contact type; the 
white bars represent the intraresidual contacts, light gray bars represent sequential contacts, gray 
bars represent medium range contacts and black bars represent long range contacts. Both termini 
of the peptide and the tyrosine 28 show the most long range contacts and the side chain of 
tyrosine 28 is oriented towards the core of the peptide. 
The chart (figure 3.24) shows that the N- and C-termini of the peptide as well as the 
tyrosine side chain contain the most long range contacts (black bars). This indicates that 
both termini constitute the peptide core.  
Analysis of the NOSEY-spectrum of DEFA1 showed that the amide proton of C31 is 
correlated with the beta-proton of the C10 and the alpha-proton of C2 is correlated with 
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beta-proton of C32. Therefore, the combination of the cysteine-residues is represented 
in the following pattern: C2-C32, C4-C20 and C10-C31. This topology matches the 
characteristic topology of disulfide bonds of all known alpha-defensins. 
The final tertiary structure of DEFA1 was calculated using the simulated-annealing 
protocol of CYANA 2.1 program performed in dihedral angles space. The identified 
resonance signals in the NOSEY-spectrum were then converted to distance restraints. 
The converted 230 distance restraints were used for structure calculation.  
Based on these data, 100 structures were calculated and 10 structures were selected 
according to the lowest target functions that represent the solution conformations of 
DEFA1. The table 3.1 represents the main parameters of CYANA structure calculation 
and the φ‐ and ψ‐dihedral angles of the peptide backbones of the structures. A very 
important parameter of CYANA structure calculation is that the selected structures 
should not violate the distance restraints or the violated distance restraints have to be 
smaller than 0.5 Å. The selected structures of DEFA1 with the lowest target functions 
show no violation of distance restraints. 
Table 3.1: Structural statistical data for the selected structures of DEFA1 with the lowest target functions. 
The structures showed no violated distance constraint, rmsd = root mean square deviation in Å. 
Distance restraints  
Intraresidual (i – j=0)       87 
Sequential (|i – j|=1)       64 
Medium range (2≤|i - j|≤4)       13 
Long range (|i - j|≥5)       48 
Disulfide bonds        18 
All distance restraints     230 
Pairwise rmsd for residues 1–34 in Å  
Mean global backbone rmsd     1.13 +/- 0.19 
Mean global heavy atom rmsd    1.87 +/- 0.23 
Pairwise rmsd for residues 3-21 and 28-32 in Å  
Mean global backbone rmsd    0.63 +/- 0.11 
Mean global heavy atom rmsd    1.43 +/- 0.21 
Ramachandran plot (mean values for all 10 structures)  
Most favored regions (%)     42.4 
Additional allowed regions (%)    52.4 
Generously allowed regions (%)      4.8 
Disallowed regions (%)       0.3 
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The Ramachandran plot is used to visualize the backbone dihedral angles psi (ψ) 
against phi (φ) of all the amino-acid residues and to validate the selected structures 
[109].  
The Ramachandarn plot of the best 10 structures is shown in figure 3.25. The psi (ψ) 
and phi (φ) of each amino-acid residue were represented as potential energy. The colors 
indicate the differences in energy level. The highest potential energy area (white) 
represents the disallowed regions. Only 0.3% of the dihedral angles are in the 
disallowed regions, which corresponds to amino-acid residue leucine 30. On the other 
hand, the generously allowed regions (grey) represent 4.8% , the additional allowed 
regions (light blue) represent 52% and the most favored regions (blue) with the lowest 
potential energy represent 42% of the dihedral angles. Nearly all the residues are 
located in the allowed regions (99.7%). Only Leu 30 is located in the disallowed regions.  
The data show that most of the amino-acid residues dispose dihedral angels, for ψ the 
value is between 45° and 180° and for φ is from -180° to -45°. The corresponding 
conformation of the dihedral angels in these structures is characteristic for beta-sheet 
elements.  
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Figure 3.25: Ramachandran plot of the best 10 structures of DEFA1. Both dihedral angles (psi 
and phi) of all amino-acid residues are distributed in different regions according to their potential 
energy. Blue color refers to most favored regions, which represent the lowest potential energy, 
light blue represents additional allowed regions, grey denotes generously allowed regions and 
white regions represent the disallowed regions, which have the highest potential energy. 99.7% of 
the amino-acids residues are in the allowed regions. Only Leu 30 is located in the disallowed 
region. 
Next, the best 10 structures were superimposed to represent the tertiary structure of 
DEFA1. Figure 3.25 (A) shows the structure ensemble based on a superposition onto 
the segments spanning residues 3–21 and 28–32, which make up 70% of the peptide. 
The structures differ at the N-, C-termini and in the segment spanning residues 20-24. 
This indicates a high flexibility of the molecule in these regions. The tertiary structure of 
one of the 10 structures (structure number 4), which has the lowest rmsd to the average 
structure, was selected and is shown in figure 3.26 (B).  
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Figure 3.26: The tertiary structure of DEFA1. (A) Spaghetti representation of the ensemble of the 
best 10 calculated structures with the lowest target functions. (B) Ribbon diagram of structure 
number 4, which was selected to be representative for the average structure. N and C denote N 
and C-termini, respectively, DSB refers to disulfide bond. Figures (A and B) were illustrated using 
MOLMOL program. 
The predominant secondary structure of DEFA1 is beta-strand as shown in the ribbon 
diagram in figure 3.26 (B). DEFA1 comprises three beta-strands (β1, β2 and β3) arrange 
in an anti-parallel manner. The N-terminus of DEFA1 consists of a flexible and 
unstructured region of two amino acid residues, followed by a first beta-strand (β1). The 
first disulfide bond, DSB1 (C2-C32) positions the β1 closer to the core of the peptide. 
The β1 is followed by the first long loop (loop1) and it connects the β1 to the β2. The 
second disulfide bond, DSB2 (C4-C20), stabilizes this loop. β2 is followed by a the 
second loop (loop2), which connects β2 to the C-terminal β3, which is stabilized by the 
third disulfide bridge, DSB3 (C10-C31).  
The electrostatic surface potential of DEFA1 was calculated (figure 3.27). The 
uncharged areas contain the hydrophobic amino-acid residues, represented in white 
color, while the colored areas represent hydrophilic amino-acid residues. The positive 
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charges are shown in blue and the negative in red (figure 3.27). DEFA1 molecule shows 
a globular protein shape with two almost hydrophobic faces that are separated from 
each other by a belt of positive charges.  
 
Figure 3.27: The electrostatic surface potential of DEFA1 from different views. Four faces are shown 
differing by a 90° each. The positive charged regions are colored in blue and negative charged regions in 
red. The distribution of hydrophobic amino-acid residues is represented in white.  
 
3.2.5 Structural Comparison of DEFA1 with other Alpha-defensin Family 
Members 
Sequence homology analysis of DEFA1 with other alpha-defensin family members 
revealed that DEFA1 is a homolog to Paneth-cell-specific human alpha-defensin 5 
(HD5) [86]. As shown in figure 3.28 (A), DEFA1 structure adopts a typical alpha-defensin 
fold with a core structure consists of three antiparallel β-strands stabilized by three 
intramolecular disulfide bonds. The tertiary structure of DEFA1 shows a high similarity to 
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the tertiary structure of human neutrophil peptide 3 (HNP3) and alpha-defensin 5 (HD5) 
(figure 3.28 B, C).  
  
Figure 3.28: The tertiary structures of DEFA1, HNP3 and HD5. A) DEFA1. B) HNP3 (PDB ID: 
1DFN. C) HD5 (PDB ID: 1ZMP). The three peptides comprise three antiparallel beta-strands. The 
beta-strands of all three peptides show the same orientation. N and C signify the N-and C-
terminus, respectively. 
Like HNP3 and HD5, DEFA1 has a small unstructured N-terminal region, followed by the 
first β1. β1 is followed by the first loop, which connects β1 to β2. β2 is connected to β3 
by the second loop. The beta-strands in DEFA1 show the same orientation as in HNP3 
and HD5. Compared to HD5 and HNP3 the second loop in DEFA1 is longer and beta-
hairpin is not distinctive formed like in HD5 and HNP3. The termini of DEFA1 are apart 
in comparison to termini of HD5 and HNP3, which are much closer to each other. 
Due to high identity between DEFA1 and HD5 surface potential of DEFA1 is compared 
with HD5. Figure 3.28 shows the electrostatic surface potential of DEFA1 and HD5. 
HD5, in contrast to DEFA1, forms dimers in solution. In addition, HD5 peptide 
(monomer) forms a globular shape with an extension at the N-terminus (figure 3.28 (A)). 
The positive charges of the HD5 are located on one region, while the only one negative 
charge is located on the other side (rotation 180°). These charged areas of HD5 are 
separated by a narrow uncharged section (figure 3.28 (A)). 
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Whereas high identity between the peptides and the number of arginine residues almost 
equal (HD5 6 and DEFA1 7 residues) the distribution of charges on the surface of HD5 
and DEFA1 is completely different (figure 3.29). DEFA1 displayed an amphipathic 
structure with hydrophobic residues forming two hydrophobic areas and positively 
charged residues forming a hydrophilic ring, as shown in figure 3.27. While in DEFA1 
positive charges appear to be dispersed about the perimeter, the hydrophobic regions 
appear to join around one side of the molecule. This charges distribution of DEFA1 
results in one region of positive residues, one of charged-uncharged residues and one 
of hydrophobic residues, which contains two negative charges of E14 and D22 (figure 
3.27).  
  
Figure 3.29: The electrostatic surface potential of DEFA1 and HD5. The figure shows the 
distribution of the positive and negative charges on the surface of HD5 as monomer (A) and 
DEFA1 (B). Positively and negatively charged regions are represented in blue and red, 
respectively, white color represents the hydrophobic residues. 
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4 Discussion 
4.1 NOD2 CARD2 
The Nucleotide binding and oligomerization domain containing protein 2 (NOD2) is an 
intracellular pattern recognition receptor that regulates nuclear factor Kappa B (NF-
Kappa B) activation and mutations in NOD2 were linked to Crohn’s disease [19]. NOD2 
contains two CARDs domain (CARD1 and CARD2), one NOD domain and one LRR 
domain [18].  
CARDs are protein-protein interaction domains, which belong to the death domain (DD) 
superfamily. They facilitate homo- or / and hetero-oligomerization of proteins and play a 
key role in many cellular processes, like apoptosis, cancer, inflammation and 
development of auto-inflammatory diseases by activating caspase-1, caspase-8 or NF-
kappa B [35]. Investigations of the interaction between the CARD domains of Apaf1 and 
caspase-9 ([110]) as well as between the CARDs of RAIDD and caspase-2 [38] revealed 
that interactions between these domains are primarily electrostatic. 
NOD2 CARD2 is involved in signaling of NOD2 and of note, a NOD2-short isoform 
(NOD2-S) (the first 126 amino acid residues of NOD2) acts as a regulatory inhibitor of 
NOD2 in the colon [44]. Recently, it was shown that both CARD domains of NOD2 are 
involved in oligomerization of NOD2 after stimulation with MDP in the presence of ATP 
and magnesium-ions [28].  
In the present work, a protocol for the expression and purification of NOD2 CARD2 was 
established to facilitate the investigation of NOD2 CARD2 function in vitro and provide 
the basis for structure determination. 
The borders of the NOD2 CARD2 domain were set according to the sequence of other 
known CARD domains. NOD2 CARD2 has a predicted molecular weight of 11.35 kDa 
and an pI of 9.41.  
A TEV cleave site was cloned by PCR directly at the N-terminus of NOD2 CARD2. The 
construct was cloned into the two different bacterial expression vectors. To verify 
expression and solubility of His-TEV-NOD2 CARD2 and Trx-TEV-NOD2 CARD2 fusion 
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proteins, an expression test was performed using various bacterial expression strains. 
Both fusion proteins were expressed in inclusion bodies. 
The fusion proteins were isolated from inclusion bodies and renatured by dialysis; Trx-
TEV-NOD2 CARD2 fusion protein was stabile in Tris buffer pH 8, whereas His-TEV-
NOD2 CARD2 was stable only in buffer systems (acetate pH 5 and CAPS pH 12). In 
such buffer systems with low or high pH the fusion protein is not cleavable neither using 
TEV nor thrombin proteases. 
Therefore, the work was continued with the Trx-TEV-NOD2 CARD2 fusion protein. The 
DLS analysis showed that the solution of fusion protein was monodisperse. However, its 
hydrodynamic radius was larger than it expected size, indicating that it may be present 
in small soluble oligomers. The CD-spectroscopy experiments and Ellman’s test showed 
that the protein was refolded and all four cysteine residues are involved in disulfide 
bonds.  
The fusion protein contains both protease cleavage sites (TEV and enterokinase) (figure 
2.2) and was proteolytic cleaved. Cleavage of the fusion protein by the TEV protease 
induced instability in the cleaved NOD2 CARD2 fragment that led to precipitation. In 
contrast, cleavage of the fusion protein by the enterokinase resulted in a stable NOD2 
CARD2 fragment, which was isolated using RP-HPLC. The NOD2 CARD2 fragment 
containing additional 23 amino-acid residues was named as 23aa-NOD2 CARD2.  
The additional 23 residues gave somehow stability to NOD2 CARD2. These amino-acid 
residues are (AMADIGSEFELRRQASENLYFQG). Analysis of the secondary structure 
using secondary structure prediction programs showed that these residues have the 
ability to build an alpha-helix. The peptide was investigated on its potential to form 
secondary structure three times by using three different secondary structure prediction 
programs. The results of all three prediction showed that the peptide displays an alpha-
helical structure. The additional alpha-helix reduces oligomerization and prevents the 
precipitation of NOD2 CARD2 after cleavage.  
CARD domains have 6 to 7 antiparallel alpha-helixes and they are heat sensitive [35]. 
CD spectroscopy of 23aa-NOD2 CARD2 (figure 3.10) demonstrated that the protein 
contains only alpha-helices.  
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Analysis of the heat stability of 23aa-NOD2 CARD2 showed that the protein non-
reversible unfolds at Tm=55 °C (figure 3.11). A comparison of the melting temperatures 
of 23aa-NOD2 CARD2 to NOD2 CARD2, which unfolds at Tm= 38.0 [111] highlights that 
23aa-NOD2 CARD2 unfolds at higher temperature. Compared to the melting 
temperatures of other known CARD domains such Apaf-1 CARD (Tm=59.7 °C), 
procaspase-9 CARD (Tm=53.4 °C) and NOD1 CARD (Tm=78.0 °C) [111], 23aa-NOD2 
CARD2 unfolds at similar temperature. Heating of 23aa-NOD2 CARD2 at 40 °C for short 
time led to formation of large oligomers (figure 3.14), however the protein did not unfold, 
suggesting that the covalent link of the additional 23 residues might enhance the thermal 
stability of the whole molecule.  
Friehd et al reported that NOD2 CARD1 and NOD2 CARD2 were expressed as one 
construct to overcome the expression problems. To isolated single domains, a thrombin 
cleavage site was cloned between the CARDs domains. Using this strategy they were 
able to produce single CARD domains of NOD2 [111].  
Compared to NOD2 CARD2 [111], 23aa-NOD2 CARD2 is salt sensitive. Addition of 150 
mM NaCl to the protein in phosphate buffer (figure 3.15) led to formation of high order 
oligomers.  
The additional peptide on one hand might enhance the thermal stability and on other 
hand worsens salt stability of 23aa-NOD2 CARD2.  
NOD2 is the only member of the NOD-like receptor that contains two N-terminal CARD 
domains (CARD1 and CARD2) and the presence of both CARDs is vital for NOD2 
functionality. On one hand, the NOD2 CARDs (1 and 2) have to be expressed as one 
construct due to stabilization effect of the both CARDs domain on each other as 
reported by Fridh et al. On the other hand, NOD2 CARD2 might need only the last helix 
(number 6) of NOD2 CARD1 but not the whole domain to be stable. It is possible that 
both domains (CARD1 and CARD2) share this helix. 
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4.2 Equine Alpha-Defensin (DEFA1) 
DEFA1 is an equine alpha-defensin, which was identified and characterized by Bruhn et 
al. The peptide displayed antimicrobial activity against Gram positive, Gram negative 
bacteria and fungus. DEFA1 is only expressed in the small intestine of equine.  
The synthetic DEFA1 peptide was refolded and purified using RP-HPLC and its activity 
was tested against pathogens [88]. Schlusselhuber et al suggested that DEFA1 could be 
a potential therapeutic antibiotic peptide against R. equi and S. zooepidemicus. 
Therefore, determination of the tertiary structure of DEFA1 helps in defining its 
mechanism of action.  
The observed activity of DEFA1 against R. equi and S. zooepidemicus confirms that the 
peptide is present in a folded form and CD-spectroscopy of DEFA1 showed that the 
peptide contains beta-strands. 
Determination of the solution structure of DEFA1 was reached by means of 
homonuclear 1H-2D-NMR spectroscopy. DEFA1 is composed of 34 amino-acid 
residues. In ideal case, all 34 amino acid residues should be identified. In the TOCSY-
experiment, all the residue’s spin systems could be detected. However, the sequential 
assignment of DEFA1 showed that only 30 residues could be assigned using 1H-2D-
homonulear TOCSY and NOESY spectra. The amino-acid residues Cys20, Ileu2, Asp22 
and Lys24 could not be assigned.  
The results of the Ellman’s test and mass spectrometry of purified DEFA1 indicated that 
all six cysteine residues in the molecule are oxidized and they form three disulfide 
bridges. According to the conserved disulfide bridge pattern of alpha-defensins [55], the 
disulfide bonds should be formed in DEFA1 between Cys2 and Cys32, Cys4 and Cys20 
and Cys10 and Cys31.  
Analysis of NOEs derived from the NOESY-spectrum displayed that Cys2 correlated 
with Cys32 and Cys10 with Cys3. However, no correlations were found between the 
protons of Cys4 and Cys20 side chains. Despite of that, the third disulfide bond is 
predicted to be between Cys4 and Cys20 because there is no other possibility to form a 
third bond. In addition, structure calculations using CYANA program with different 
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combination of paired cysteine residues were done to ascertain the results. The 
calculations showed that the most favourable combination of disulfide bridges pattern, 
according to the target function values, was the conserved alpha-defensins disulfide 
bridges pattern. 
The results conclusively illustrate the 3D-structure of equine DEFA1 (figure 3.26). The 
tertiary structure of equine DEFA1 is similar to other known alpha-defensins (figure 
3.28). The 3D-structure of DEFA1 shows that it consists of three beta-strands, including 
a loop, which align to form antiparallel beta-strands.  
DEFA1 contains three antiparallel beta-strands. The beta-strands are short in compared 
to HD5 and HNP3. However, the orientation of all beta-strands of DEFA1 corresponds to 
the beta-strands orientation of the alpha-defensin fold, which is characterized by 
formation of 3 antiparallel beta-strands, which are stabilized by 3 intramolecular disulfide 
bonds [112]. The beta-strands of DEFA1 are short compared to beta-strands of HNP3 
and HD5, it might due to missing medium range contacts between DEFA1 residues. 
The NMR-data showed that in contrast to all human alpha-defensins [113], [112], 
DEFA1 is monomeric in solution like cryptdin-4 [114], a mouse Paneth cell alpha-
defensin.  
Electrostatic surface potential analysis helped to understand the structure-function 
relationship of DEFA1 (figure 3.27). The surface potential analysis displays a unique 
charges distribution on DEFA1 surface, compared to the surface potential distribution of 
human alpha-defensins. The common character of surface potentials of all human 
alpha-defesins is that the charged resides are located on one side of molecules and 
uncharged residues on the opposite side to form an amphipathic character [112]. The 
results of DEFA1 showed that the positive charges are located about the perimeter and 
the hydrophobic regions are located on the two areas of the molecule.  
Bruhn et al investigated the interaction between DEFA1 and different liposomes using 
CD-spectroscopy and tryptophan fluorescence-emission spectroscopy [86]. They 
showed that DEFA1 interacted with negative charged liposomes (phosphatidylglycerol 
liposomes [PG-liposomes]) and the fluorescence emission of tryptophan changed after 
incubation of the PG-liposomes with the peptides. It means that DEFA1 translocates 
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through the lipid layer. These effects were not observed, as the uncharged liposomes 
were incubated with DEFA1. Incubation of the PG-liposomes with DEFA1 led to a 
reduction of the intensity of the CD-ellipticity signal. Schlusselhuber et al have confirmed 
these results [88]. The authors showed that incubation of DEFA1 with PG-liposomes led 
to formation of precipitates. Dr. Sascha Jung investigated the effect of DEFA1 on 
negative and neutral liposomes using DLS (personal communication). He showed that 
incubation of DEFA1 with PG-liposomes led to the formation of large aggregates, while 
no effect was monitored, when uncharged liposomes were used.  
DEFA1 is homolog to human alpha-defensin 5 (HD5) [86]. The precise mechanism of 
antimicrobial action of human enteric alpha-defensin is unclear [115]. HD5 performs 
different mechanisms of action against Gram-positive and Gram-negative bacteria [115]. 
The mechanism of action of DEFA1 is not intensively investigated. Bruhn et al described 
the mechanism of action of DEFA1 using a minimalistic system (depolarization of 
liposomes as a measurement of pore-forming activity) [86]. He proposed that the peptide 
has a moderate pore-forming activity. Schlusselhuber et al showed that anionic vesicles, 
as substrates for DEFA1, had revealed an aggregation pattern for the effects of DEFA1 
on the anionic vesicles [88]. Scanning electron microscopy of R. equi treated with 
DEFA1 showed that incubation of DEFA1 with bacteria leads to clustering of bacteria. 
However, Schlusselhuber did not discuss this phenomenon.  
Interestingly, the charge distribution on the surface of DEFA1 is very similar to 
Hydramacin-1, a Hydra antimicrobial peptide, which was characterized by Jung et al 
[116] and cryptdin-4 (Crp4), a mouse intestinal Paneth cells alpha-defensin [114]. The 
peptides exhibited an amphipathic structure and the hydrophobic residues are located 
on two areas, while the positive charge residues form a hydrophilic ring. The initial step 
of the bactericidal mechanism of hydramacin-1 is aggregation of treated bacteria before 
the extensive killing effect. The aggregation phenomenon was also observed once 
negative liposomes were used as substrate for hydramacin-1 [116]. In contrast to 
hydramacin-1, Crp4 interacts with the bacterial membrane and directly permeabilizes 
them without formation of initial bacterial aggregation step [117], [114]. 
Taken together, these observations indicate that DEFA1 is similar to hydramacin-1 in the 
charges distribution on the surface and at least in the initial step of the killing 
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mechanism. It is tempting to speculate that mode of action of DEFA1 is similar to the 
mode of action of hydramacin-1 and the killing mechanism of DEFA1 can be describe 
using the proposed model of mode of action of hydramacin-1. The both hydrophobic 
areas of DEFA1 submerge into the outer membrane of two neighboring bacterial cells. 
Thus, negative charges of the phospholipids of the membrane surfaces are 
compensated by the set of positive charges around the perimeter of the molecule. This 
electrostatic interaction could enhance the aggregation of bacterial cells at the point of 
immersion. Hydrophobic and electrostatic interaction stabilizes the peptide-lipid 
complex. However, this statement is speculative and the exact bactericidal mechanism 
of action of DEFA1 on various Gram-negative, Gram–positive bacterial and fungus has 
to be identified. Elucidating the detailed mechanism of action will require further 
investigations of structure-functions and structure-actions using putative physiological 
targets. 
 
4.3 Prospective 
4.3.1 NOD2 CARD2 
Activated NOD2 binds to the protein kinase RICK to direct NF-kappa B-mediated 
cytokine responses and the interaction between the both proteins is mediated via CARD 
domains [18]. To understand the interaction, in vitro functional studies and structural 
information are needed. The established protocol for expression and purification of 
NOD2 CARD2 in the present thesis is the basis for future investigations of NOD2 
CARD2 interaction with other domains of NOD2 and with other CARD containing 
proteins. Future experiments including, determination of structures of NOD2 CARD2 and 
NOD2 NOD1 might help in a development of strategies for therapies of people with 
NOD2-hyperactivation state [118].  
Moreover, define NOD2 mechanism of activation by NOD2 LRR-ligands complex and 
how this activation is regulated will help in understanding how the mutations in NOD2 
link to Crohn’s disease and it might be the first step for development a therapy 
[119],.[120]. 
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4.3.2 DEFA1 
The theatrical increase in resistance to antibiotics by pathogens has made a major 
medical need for new anti-infective products. For example, more than 25% of K. 
pneumoniae isolates found in 11 countries of EU, are resistant to third-generation 
cephalosporin. Only in EU, it was estimated that in 2007 about 25 000 people died from 
an infection due to multidrug-resistant bacteria. It might be the situations in other many 
countries even worse [121]. Therefore, it is important to develop new drugs to treatment 
people most affected. One promising potential is utilizing of AMPs due to development 
of resistance by bacteria is very rare and AMPs have a board spectrum of antimicrobial 
activity [51]. Therefore, optimization of mode of action, as example, by design chimeric 
peptide [122], and definition of their mode of action will accelerate their medical 
application. Determination of the tertiary structure of DEFA1 provided a better 
understanding of the mode of action of this defensin.  
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5 Summary 
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is a cytosolic 
pattern recognition receptor (PRR). It binds muramyl dipeptide and consists of two N-
terminal caspase-activating and recruitment domains (CARD) (CARD1 and CARD2), 
one central nucleotide-binding oligomerization domain (NOD) and C-terminal leucin rich 
repeats (LRR). The CARD2 domain of NOD2 (NOD2 CARD2) is a member of death 
domain superfamily, which is characterized by holding six antiparallel alpha-helixes. 
NOD2 CARD2 is involved in signaling of NOD2. Recently it was shown that NOD2 
CARDs (CARD2 and CARD2) are involved in the oligomerization of NOD2 in vitro, 
however the precise function of CARD2 domain in NOD2 is still unclear.  
In the first part of this thesis a protocol for expression, purification and refolding was 
established to be the basis for tertiary structure determination and in vitro functional 
investigations. 
 
The second part of the thesis deals with determination of tertiary structure of equine 
alpha-defensin 1. The peptide shows high killing activity against Gram‐positive, Gram‐
negative bacteria and fungus and it is a potential antibiotic peptide against R. equi and 
S. zooepidemicus. 
To elucidate the mechanism of action of equine alpha-defensin 1 the solution structure 
was determined by two‐dimensional homonuclear NMR‐spectroscopy. The synthetic 
peptide was refolding, purified and NMR spectra of the purified peptide were recorded. 
The tertiary structure contains a cysteine‐stabilized β‐strands motif and shows a high 
structural homology to other alpha‐defensins. Compared to the surface potential of 
human defensins, DEFA1 displays an unusual distribution of the charges. The similarity 
between DEFA1 and hydramacin-1 in charges distribution and inducement of 
aggregation in treated bacterial cells and liposomes supports the hypothesis that the 
mode of action of DEFA1 is similar to the mode of action of hydamacin-1.  
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6 Zusammenfassung 
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) ist ein 
intrazellulärer PRR (pattern recognition receptor). Dieser Rezeptor bindet 
Muramyldipeptid und besteht aus zwei N-terminalen caspase-activating and recruitment 
domains (CARD1 und CARD2), einer zentralen nucleotide-binding oligomerization 
domain (NOD) und einer C-terminalen leucin rich repeats (LRR). Die CARD2 Domäne 
von NOD2 (NOD2-CARD2) ist ein Mitglied der Todesdomäne Superfamilie (death 
domain superfamily), die durch sechs antiparallele alpha-Helices gekennzeichnet ist. Die 
NOD2-CARD2 ist an der Weiterleitung der Signal von NOD2 beteiligt. Kürzlich wurde 
gezeigt, dass die CARD-Domaänen von NOD2 (CARD1 und CARD2) auch an der 
Oligomerisierung von NOD2 in vitro beteiligt sind, die genaue Funktion der CARD2-
Domäne in NOD2 ist jedoch bis jetzt unklar.  
Im ersten Teil dieser vorliegenden Arbeit wurde ein Protokoll für die Expression, 
Reinigung und Rückfaltung etabliert, um die Basis für Tertiärstrukturaufklärung und in 
vitro funktionelle Untersuchungen von der NOD2-CARD2 Domäne zu schaffen. 
 
Der zweite Teil der vorliegenden Arbeit behandelt die Tertiärstruktur des Equine Alpha-
Defensins 1 (DEFA1). Das Peptid verfügt über eine hohe antimikrobielle Aktivität gegen 
Gram-positiven und Gram-negativen Bakterian sowie gegen Pilze. Um den 
Wirkmechanismus des Peptids näher zu bestimmen, sollte die Tertiärstruktur des 
DEFA1-Peptides mittels zweidimensionaler homonuklearer (2D-1H) NMR‐Spektroskopie 
aufgeklärt werden. 
Zu diesem Zweck wurde ein Renaturierung- und Reinigungsprotokoll für DEFA1 
etabliert. Von dem gereinigten und renaturierten Peptid wurden 2D-1H‐NMR‐Spektren 
aufgenommen. Die aufgeklärte Tertiärstruktur des DEFA1 entspricht einem durch 
Disulfidbrücken stabilisierten β‐Faltblattmotiv und weist eine hohe strukturelle 
Verwandtschaft zu den Alpha‐Defensinen auf. Im Vergleich zu Oberflächenpotentialen 
von humanen Alpha‐Defensinen zeichnet sich die Oberflächenpotential des DEFA1 
durch eine ungewöhnlich Verteilung der Ladungen aus. Die Ähnlichkeit zwischen 
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DEFA1 und Hydramycin-1 betzüglich der Oberflächenverteilung von Ladungen und 
Veranlassung der Aggregation in behandelten Bakterienzellen und Liposomen 
unterstützt die Hypothese, dass die Wirkungsweise der DEFA1 der Wirkungsweise von 
Hydamacin-1 ähnelt. 
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8 Appendix 
8.1 Abbreviations 
µg    Microgram 
1D    One-dimensional  
2D     Two-dimensional  
3D    Three-dimensional 
A     Alanine  
Å    Angstrom 
AD    Acid transactivation domain 
AI     After induction  
Ala     Alanine  
Aliph.    Aliphatic 
AMP    Antimicrobial peptide 
APS     Ammonium peroxydisulphate  
Arg     Arginine  
Asn     Asparagine  
ATP    Adenosine-5'-triphosphate 
B     Before treatment 
BIR    Baculoviral inhibitory repeat 
Bo    Magnetic field 
bp    Base pairs 
C     Cysteine  
CARD    Caspase recruitment domain 
CD     Circular dichroism  
cDNA    Complementary DNA 
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CIITA    MHC class II transactivator 
Cys     Cysteine  
D     Aspartic acid  
DAMP    Danger associated molecular pattern 
DC    Dendritic cells 
DD    Death domain superfamily 
DED    Death effector domain 
DEFA1   Alpha-defensin 1 
DEFB    Beta-defensin 
DLS    Dynamic light scattering 
DNA    Deoxyribonucleic acid 
dNTP    Deoxyribonucleotide 
E     Glutamic acid 
E 1, E 2   Elution steps  
E.coli     Escherichia coli  
F    Fraction 
FID     Free induction decay  
FIIND    Function-to-find domain 
G     Glycine  
Gdn ·     HCl Guanidine hydrochloride  
Gln     Glutamine  
Glu     Glutamic acid  
H     Histidine  
HBD    Human beta-defensin 
HD    Human defensin 
HDP    Host defense peptide 
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HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid  
His     Histidine  
HNP    Human neutrophil peptide 
Hα    Alpha-proton 
Hβ    Beta-proton 
Hγ    Gama-proton 
I    Isoleucine  
I    Spin 
IB    Inclusion body 
IBD    Inflammatory bowel disease 
IFN    Type I interferon 
Ile    Isoleucine  
IPTG     Isopropyl-β-D-1-thiogalactopyranoside  
IRF3    Interferon regulatory factor 3 
K     Lysine  
kDa     Kilo Dalton  
L     Leucine  
LB     Luria Broth  
Leu     Leucine  
LPS    Lipopolysaccharides 
LRR    Leucine rich repeat 
MALDI-TOF    Matrix-assisted laser desorption/ionisation-time of flight 
MAPK    Mitogen-activated protein kinase  
MAMP   Microbial associated molecular pattern 
MAVS    Mitochondrial antiviral-signaling protein 
MDP    Muramyl dipeptide 
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ms     Millisecond  
MS    Mass spectrometry 
MW     Molecular weight  
MWCO   Molecular-weight cutoff 
N     Asparagine  
NAIP    Neuronal apoptosis inhibitor protein 
NF-Kappa B    Nuclear factor kappa B 
Ni+2-NTA    Nickel-nitrilotriacetic acid  
NK cells    Natural killer cells  
NLR    NOD-like receptors 
NLRC    CARD-containing subfamily 
NLRP    Pyrin containing 
NMR     Nuclear magnetic resonance  
NOD    Nucleotide binding and oligomerization domain 
NOD1    Nucleotide-binding oligomerization domain containing protein 
1 
NOD2    Nucleotide-binding oligomerization domain containing protein 
2 
NOESY    Nuclear Overhauser and exchange spectroscopy  
OD     Optical density  
P     Proline  
P    Pellet 
PAMPs    Pathogen-associated molecular patterns  
PC     Phosphatidylcholine  
PCR    Polymerase Chain Reaction 
PE     Phosphatidylethanolamine  
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ppm    Parts per milion  
Pro     Proline  
PRR    Pattern-recognition receptors 
PYD    Pyrin domain 
Q     Glutamine  
R     Arginine  
R. equi   Rhodococcus equi 
RF     Radio frequency  
RF    Radio-frequency electromagnetic radiation 
RICK    Serine threonine kinase 
rmsd     Root mean square deviation  
RNA    Ribonucleic acid 
ROS    Reactive oxygen species 
RP-HPLC   Reverse Phase‐High Performance Liquid Chromatography 
rpm    Round per minute 
S     Serine  
S    Supernatant 
S. zooepidemicus   Streptococcus zooepidemicus 
SDS     Sodium dodecyl sulphate  
SDS-PAGE    Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Ser     Serine  
T     Threonine  
T1    Longitudinal relaxation time 
T2    Transverse relaxation time 
TBA    Tris-borate-EDTA buffer 
TEMED    N, N, N’, N’- tetramethylethylenediamine  
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TEV    Tobacco Etch Virus 
TFA    Trifluoroacetic acid 
TLR    Toll-like receptors 
TMS    Tetramethylsilane 
TOCSY    Total correlation spectroscopy  
TRIS     Trishydroxymethylaminomethane  
U    Unit 
UV     Ultraviolet  
V    Volt 
V/V    Volume per volume  
W     Washing step  
Y     Tyrosine 
δ    Chemical shift 
μ    Magnetic moment 
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